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P(,$4*#0,.4(!
! MR!
*.$+0,&H! .(*#0+/! 'L4L,4/./! '(*! /+(+/0+(0+! .(! .(/#&.(=L$4*#0.()! 0+&&/!'004<L'(.+*!UH!0H,4/5+&+,4(!$+'$$'()+<+(,/!'(*!W14!CT@'/+!*+$+)#&',.4(!NgY8!O+$+*.,'$H! /+(/4$H! '(*! '#,4(4<.0! (+#$4L',1H! ,HL+! N! 7O^I[N9! ./! '! $'$+!'#,4/4<'&! *4<.('(,&H! .(1+$.,+*! 'B4('&! (+#$4L',1H8! P(,+$+/,.()&H! .,! 1'/! U++(!*./04:+$+*! ,1',! 0+$,'.(!<.//+(/+!<#,',.4(! .(! ,1+! )+(+/! +(04*.()! ^@TFKN! '(*!^@TFKR!0'#/+!,1./!*./+'/+!NgZ8!^H<L,4</!42!O^I[N!'$+!L$4)$+//.:+!&4//!42!L'.(!'(*! ,+<L+$',#$+!/+(/',.4(!/,'$,.()! .(! ,1+! &4-+$! &.<U/!'(*!+BL'(*.()! ,4!#LL+$!+B,$+<.,.+/! Ngg8! @4/,=<4$,'&! +B'<.(',.4(! 42! O^I[N! L',.+(,/! *+<4(/,$',+*!+B,$+<+!*+)+(+$',.4(!42!*4$/'&!$44,!)'()&.4(!0+&&/!'(*!*+/,$4H+*!<H+&.(!/1+',1!24$<! L+$.L1+$'&! (+$:+/! Ngg8! T1+!<+(,.4(+*! O^I[N!<#,'(,! ^@T! :'$.'(,/! /14-!.(0$+'/+*! /#U/,$',+! /L+0.2.0.,H! 24$! '&'(.(+! ,1#/! .(*#0.()! '00#<#&',.4(! 42!*+4BH^F8!P(!'004$*'(0+!1.)1&H!+&+:',+*!*+4BH^F!&+:+&/!-+$+!24#(*!.(!L&'/<'!'(*!,.//#+! 42! '(! O^I[N!<4#/+!<4*+&! NgS8! T1+! (+#$4,4B.0! +22+0,! 42! N=*+4BH^I!-'/!04(2.$<+*! 4(! 0#&,#$+*! 01.05+(!*4$/'&! $44,! )'()&.4(! 0+&&/!-1+$+! '! $+*#0,.4(! 42!(+#$.,+!(#<U+$!'(*!&+(),1!-'/!*+,+0,+*!NgV8!O4-+:+$!,1+!<+01'(./</!UH!-1.01!*+4BH^F! .(*#0+! (+#$4('&! *+',1! $+<'.(/! ,4! U+! #($':+&+*8! [4,'U&H! *.'U+,.0!/+(/4$H!(+#$4L',1H! 73^[9\! ,1+!<4/,! 04<<4(!01$4(.0!04<L&.0',.4(!42!*.'U+,+/!<+&&.,#/\!./!0&.(.0'&&H!:+$H!/.<.&'$!,4!O^I[N8!I/!<+(,.4(+*!'U4:+!*.'U+,.0/!1':+!U++(! /14-(! ,4! 2$+a#+(,&H! 1':+! +&+:',+*! *+4BH^F! L&'/<'! &+:+&/! '(*! 1+(0+! ,1+!24$<',.4(!42!*+4BH/L1.()4&.L.*/!<.)1,!U+!+:+(!'//40.',+*!-.,1!3^[8!O4-+:+$\!(4,! <#01! ./! 5(4-(! 'U4#,! ,1+/+! *+4BH^F! '(*! ,1#/! <#01! <4$+! $+/+'$01! ./!$+a#.$+*!,4!#(*+$/,'(*!,1+.$!<4*+!42!'0,.4(8!@'$,!42!,1./!,1+/./!-4$5!-'/!240#/+*!,4! #($':+&! ,1+! <4&+0#&'$! <+01'(./</! 42! N=*+4BH^I=.(*#0+*! (+#$4,4B.0.,H! ,4!<'5+! ,1+! 2.$/,! /,+L! ,4-'$*/! ,1+! *+:+&4L<+(,! 42! ,1+$'L+#,.0! 'LL$4'01+/! ,4!L$+:+(,!*+4BH/L1.()4&.L.*=,$.))+$+*!(+#$4L',1.+/8!
!"#$%"&'('$)*+,&-%'$$
$ ..$
!
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!
!
0*12,(! 34! 5,*1%'6*(78! *9:1(! -6! /27'2,(8! /-,'*/:7! 9-2)(! ;(2,-;)#! AH$ #>K$ 3&6*+3'$"2E&$5&E&;+)&5$1+*&$3&6*(%&$-+33&%(+3'$235$?6(;5$2$1+*&$-+1);&F$3&%0+*G$%"23$J$#>K$3&6*+3'9$$$
@13!,1+/./!L$4_+0,/!!
! MQ!
1"!#2';,#'?#2*@!#)-#6/,#-,<7'-*;#7,5&'-5,#6'#/%&'()*#
T1+!)4'&!42!,1./!/,#*H!-'/!,4!'//+//!,1+!04(,$.U#,.4(!42!,1+!W14!CT@'/+!W'0N!,4!,1+! (+#$4('&! 1HL4B.0! $+/L4(/+8! T1+! #(*+$/,'(*.()! 42! ,1+! (+#$4('&! '(/-+$! ,4!1HL4B.'! ./! U+(+2.0.'&! 24$! +&'U4$',.()! /,$',+).+/! ,4!L$+:+(,!(+#$4('&! &4//!*#+! ,4!1HL4B.0!.(/#&,/8!!!
%
!'()%*+%J'1-.$%\)L%92]^%:40"7*(%+$-."+/%
• I('&H/./!42!1HL4B.'=*+L+(*+(,!W'0N!$+)#&',.4(!.(!<',#$+!(+#$4(/!
• %22+0,/!42!W'0N!.(1.U.,.4(!4(!OP>=Nc!.(*#0,.4(!'(*!/#U/+a#+(,!'*'L,.:+!)+(+!+BL$+//.4(!!
• K4(/+a#+(0+/! 42! '0#,+! 1HL4B.'! '(*! W'0N! .(1.U.,.4(! 4(! /#$:.:'&! 42!<',#$+!(+#$4(/!
• P*+(,.2.0',.4(! 42! L',1-'H/! <+*.',.()! W'0N=*+L+(*+(,! (+#$4('&! OP>=Nc!.(*#0,.4(!!!T1+!*','!42!,1+/+!.(:+/,.)',.4(/!$+/#&,+*!.(!'!/#U<.,,+*!<'(#/0$.L,!.(!-1.01!P!'<!2.$/,!'#,14$!7rW'0N!L&'H/!'!0$#0.'&!$4&+!24$!(+#$4('&!'*'L,',.4(!,4!1HL4B.'s\!01'L,+$!g8N98!!
!'()%*+%4"-+;%\R%92]^%:40"7*(%+$-."+/%
• I('&H/./!42!'0#,+!1HL4B.0!W'0N!$+)#&',.4(!.(!H4#()!(+#$4(/!
• 3+,+$<.(',.4(!42!,1+!+22+0,!42!W'0N!.(1.U.,.4(!42!OP>=Nc!.(*#0,.4(!!
• ^#$:.:'&!42!H4#()!(+#$4(/!*#$.()!'0#,+!1HL4B.'!'(*!W'0N!.(1.U.,.4(!!
• %22+0,/!42!C^dM!.(1.U.,.4(!4(!1HL4B.0!OP>=Nc!'00#<#&',.4(!!!
!'()%*+%1:$%.$/0"+/$%"&%J'1-.$%+$-."+/%1"%0."#"+;$8%:40"7*'%
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! MY!
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T1./! /+04(*! /,#*H! *+,+$<.(+*! ,1+! +22+0,! 42! ,1+! ',HL.0'&! /L1.()4.*! U'/+\! N=*+4BH^I\! 4(! /#$:.:'&! 42! 0#&,#$+*! 04$,.0'&! (+#$4(/! -.,1! '! /L+0.'&! +<L1'/./! 4(!<4*#&',.4(! 42! 0H,4/5+&+,4(! .(,+)$.,H! '(*! W14! CT@'/+! $+)#&',.4(8! ;4/,!.<L4$,'(,&H! -+! .(,+(*+*! ,4! $+/4&:+! ,1+! <4&+0#&'$! <+01'(./</! .(:4&:+*! .(! N=*+4BH^I=.(*#0+*!(+#$4,4B.0.,H! /.(0+! ,1./! ./! '! L$+$+a#./.,+! ,4! .*+(,.2H! 0&.(.0'&&H!$+&+:'(,!/,$',+).+/!,4!L$+:+(,!*+4BH=/L1.()4&.L.*=<+*.',+*!(+#$4*+)+(+$',.4(8!!
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• %22+0,!42!N=*+4BH/L1.()'(.(+!7N=*+4BH^I9!'(*!.,/!<+,'U4&.,+/!4(!/#$:.:'&!42!<',#$+!(+#$4(/%
• K1'$'0,+$."',.4(!42!N=*+4BH^I!+22+0,/!4(!,1+!(+#$4('&!0H,4/5+&+,4(%
• P*+(,.2.0',.4(!42!0H,4/5+&+,4(='//40.',+*!L$4,+.(/!$+)#&',+*!UH!N=*+4BH^I%
• K4(,$.U#,.4(!42!W'0N!'(*!G[d!,4!N=*+4BH^I=,$.))+$+*!(+#$4('&!*+',1%
• I('&H/./! 42! .(:4&:+<+(,! 42! [;3IW! /.)('&.()! .(! N=*+4BH^I=.(*#0+*!(+#$4,4B.0.,H%
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• K4(/+a#+(0+/! 42! N=*+4BH^I! +BL4/#$+! 4(! G[d!L14/L14$H&',.4(! '(*! 4(! LMY!&+:+&/%
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!'()%*/%-0.$;-#'1$8%'+8%'(1*>'1$8%*+%4"-+;%+$-."+/%8-.*+;%:40"7*'%b+! 2.$/,! /,#*.+*! 1HL4B.0! W'0N! $+)#&',.4(! .(! Z! 3PD! L$.<'$H! 04$,.0'&! <4#/+!(+#$4(/8! b+/,+$(! U&4,! '('&H/./! /14-+*! '2,+$! Q1! '(*! Z1! 42! 1HL4B.'! .(0$+'/+*!W'0N! L$4,+.(! &+:+&/! 04<L'$+*! ,4! (4$<4B.0! 04(,$4&! /'<L&+/! 7>.)8! SI98!P<<#(40H,401+<./,$H! 04(2.$<+*! ,1./! 4U/+$:',.4(! '/! (4$<4B.0! 0+&&/! /14-+*!:+$H!-+'5! /,'.(.()! 24$! W'0N!-1+$+'/! 1HL4B.0! 0+&&/! /14-+*! '! U$.)1,! '(*! 0&+'$!/.)('&!'2,+$!Z1!7>.)8!S`98!T4!+B'<.(+!(+#$4('&!W'0N!'0,.:.,H!/,',+!-+!#/+*!W'0!C=FP^I8!OHL4B.0! +BL4/#$+! /,$4()&H! .(0$+'/+*!W'0! '0,.:.,H! '2,+$! R1! 7RVQ8V! t! NV8S\!LuV8VN9!'(*!$+<'.(+*!+&+:',+*!#L!,4!Z1!7N]R8g!t!N8g\!LuV8VN9!04<L'$+*!,4!,1+!(4$<4B.0! 04(,$4&! 7>.)8! SK98! T1+/+! $+/#&,/! /14-! ,1',! ,1+! $+/L4(/+! ,4! '0#,+!1HL4B.'!42!Z!3PD!(+#$4(/!'0,.:',+/!W'0N!'/!4U/+$:+*!.(!<',#$+!0+&&/8!!
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! MS!
!'()%*/%(.-(*'#%&".%62Y<)Z%/1'O*#*`'1*"+%*+%4"-+;%+$-."+/%T4!L$4:+!,1',!1HL4B.'='0,.:',+*!W'0N!./!0$.,.0'&!24$!OP>=N!/.)('&.()!.(!Z!3PD!0+&&/!-+! ,$+',+*!H4#()!(+#$4(/!-.,1!YV!v;!'(*!NVV!v;!42!'!/L+0.2.0!W'0N! .(1.U.,4$!L$.4$!,4!1HL4B.0!+BL4/#$+8!b+/,+$(!U&4,!*','!/14-!OP>=Nc!'00#<#&',.4(!'2,+$!Q1!'(*! Z1\! 14-+:+$! .(1.U.,4$! ,$+',<+(,! 04<L&+,+&H! 'U$4)',+*! 42! 1HL4B.0! OP>=Nc!'00#<#&',.4(! 7>.)8! ]I98! P<<#(40H,401+<./,$H! ')'.(! 04(2.$<+*! ,1+/+! $+/#&,/!/14-.()! U'/'&! OP>=Nc! /.)('&! -.,1! 1HL4B.0! +BL4/#$+! .(*#0.()! (#0&+'$! OP>=Nc!/,'.(.()8! ^.<.&'$! ,4! b+/,+$(! U&4,! $+/#&,/! W'0N! .(1.U.,.4(! /,$4()&H! /#LL$+//+*!OP>=Nc!'00#<#&',.4(!.(!U4,1!(4$<4B.0!'(*!1HL4B.0!0+&&/!7>.)8!]`98!T1#/!W'0N!./!'!0$.,.0'&!.(*#0+*!42!OP>=Nc!/,'U.&."',.4(!.(!H4#()!(+#$4(/8!
!"#$%&#'
' ()'
'
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W+/#&,/!
! QV!
a"-+;%+$-."+/%/-.>*>$%'(-1$%:40"7*'%*+%'O/$+($%"&%!'()%'+8%62Y<)Z%T4! *+<4(/,$',+! ,1+! +22+0,! 42! '0#,+! 1HL4B.'! '(*! W'0N! .(1.U.,.4(! 4(! /#$:.:'&! 42!H4#()!(+#$4(/\!0+&&/!-+$+!,$+',+*!-.,1!W'0N!.(1.U.,4$!L$.4$!,4!1HL4B.0!+BL4/#$+!'(*!0+&&!/#$:.:'&!-'/!'//+//+*!#/.()!;TT!7>.)8!NVI9!'(*!F3O!7>.)8!NV`9!'//'H/8!`4,1! '//'H/! *','! /14-! ,1',! (+.,1+$! '0#,+! 1HL4B.'! (4$! W'0N! .(1.U.,.4(! '&,+$/!/#$:.:'&!42!.<<',#$+!(+#$4(/8!T1#/!,4&+$'(0+!,4!/14$,!L+$.4*/!42!$+*#0+*!4BH)+(!&+:+&/!*4!(4,!*+L+(*!4(!W'0N!'(*!OP>=Nc8!
!"#$%&#'
' ()'
'
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!"#$%&' ()*' +&$%,-.' .$%/"/&' 01$2&' 345,6"0' "-' 07.&-1&' ,8' 901(' 0-:' ;<!=(>?' *"%%#'+","'&,"-&".'+/&0'!-1)' /20/3/&4,'-2.'5"6&'$2.",'24,748/1'9:8;'4,'0<648/1'142./&/42#'9=8;>' ?2.' 1"%%' #$,@/@-%' ."&",7/2".' 3<' &+4' 7"&04.#>' ?A' BCC' -##-<' +-#' $#".' -#' -2'/2./1-&4,'D4,'1"%%'#$,@/@-%'9:E(;>'FA'GH=',"%"-#"'/2&4'&0"'1$%&$,"'7"./$7'+-#'7"-#$,".'&4'."&"1&'1<&4&48/1/&<'9:EI;>':4'#/J2/D/1-2&'10-2J"#'+","'43#",@".>''
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W+/#&,/!
! QR!
N(1*>$%DIbP%*/%(.*1*('#%&".%:40"7*(%62Y<)Z%'((-J-#'1*"+%*+%+$-."+/%b+!L$+:+(,+*!C^dM!'0,.:',.4(!UH!F.K&!,$+',<+(,!42!H4#()!(+#$4(/!,4!:+$.2H!4#$!1HL4,1+/./! ,1',! W'0N=*+L+(*+(,!OP>=Nc! .(*#0,.4(! .(:4&:+/! '0,.:',.4(! 42! C^dM8!b+/,+$(! U&4,! '('&H/./! *+<4(/,$',+*! ,1',!OP>=Nc! '00#<#&',.4(! .(! 1HL4B.0! 0+&&/!-'/!$+*#0+*!.(!0+&&/!,$+',+*!-.,1!RY!<;!F.K&!'(*!04<L&+,+&H!U&405+*!UH!1.)1+$!04(0+(,$',.4(/!42!F.K&!7>.)8!NNI98!P<<#(41./,401+<.0'&!'('&H/./!04<2.$<+*!F.K&=*+L+(*+(,!.(,+$2+$+(0+!-.,1!1HL4B.0!OP>=Nc!/,'U.&."',.4(!7>.)8!NN`98!E#$!$+/#&,/!.*+(,.2H!C^dM!'/!'(!.(*#0+$!42!1HL4B.0!OP>=Nc!'00#<#&',.4(!.(!H4#()!(+#$4(/8!!
!"#$%&#'
' ()'
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W+/#&,/!
! QQ!
PK)KF%!'()%'+8%1:$%.$/0"+/$%"&%J'1-.$%+$-."+/%1"%0."#"+;$8%
:40"7*'%E#$!<'(#/0$.L,! *+/0$.U+/! ,1',! (+.,1+$! '0#,+! 1HL4B.'! '&4(+! (4$! W'0N! 4$! C^dM!.(1.U.,.4(! .(*#0+*! 0+&&! *+',1! .(! <',#$+! (+#$4(/8! O4-+:+$! /.(0+! '! (#<U+$! 42!/,#*.+/!1':+!/14-(!04(0&#/.:+&H!,1',!L$4&4()+*!1HL4B.'!.(*#0+/!0+&&!*+',1!ZM\NSV\!-+! '//+//+*! ,1+! /+(/.,.:.,H! 42! <',#$+! (+#$4(/! ,4! L$4&4()+*! 1HL4B.'8!>#$,1+$<4$+! -+! *+,+$<.(+*! ,1+! +22+0,! 42! 04(,.(#4#/! .(1.U.,.4(! 42! W'0N! '(*!C^dM!4(!/#$:.:'&8!!
%
!'()%'+8%'(1*>$%DIbP%*+8-($%62Y<)Z%'((-J-#'1*"+%*+%J'1-.$%+$-."+/%
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Abstract 
The formation of 1-deoxysphingolipids, including 1-deoxysphinganine has been 
identified as major pathological player in hereditary sensory and autosomal 
neuropathy type 1. However the molecular mechanisms by which 1-
deoxysphingolipids induce neurotoxicity is unknown. To get a handle on their action, 
we treated primary neurons with the atypical sphingoid base 1-deoxysphinganine or 
its canonical counterpart C18sphinganine and studied the outcome on cell survival and 
cytoskeleton integrity. Here we demonstrate that 1-deoxysphinganine is internalized 
and metabolized to 1-deoxydihydroceramide species that mediate the neurotoxic 
effects since inhibition of ceramide synthase protected neurons from 1-
deoxysphinganine-mediated cell death. Treatment with 1-deoxysphinganine led to 
alterations of multiple components of the neuronal cytoskeleton and deregulation of 
cytoskeleton-regulating proteins like Rac1, Ezrin and insulin receptor substrate 53. 
Furthermore, 1-deoxysphinganine triggered changes in protein levels of N-methyl-D-
aspartate receptor subunit NR2B, the postsynaptic density protein 95 and induced 
cleavage of p35 to p25. Notably, blocking the N-methyl-D-aspartate receptor by MK-
801 or memantine significantly prevented the 1-deoxysphinganine-induced effects. 
Overall, our results show that mechanisms of 1-deoxysphinganine-induced 
neurotoxicity target cytoskeletal rearrangements and N-methyl-D-aspartate receptor 
signaling. This suggests that besides the stabilization of cytoskeletal structures the 
inhibition of glutamate receptors could be a potential therapeutic approach to prevent 
1-deoxysphingolipid-induced neurodegeneration.  
 
Keywords: Hereditary sensory and autosomal neuropathy type 1, lipid metabolism, 
cytoskeleton, Rac1, glutamate receptor 
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Introduction 
Sphingolipids not only participate in plasma membrane formation but are also 
important signaling molecules involved in several cellular processes (Ghosh et al., 
1990; Lépine et al., 2011; Obeid et al., 1993; Sim-Selley et al., 2009). The first step of 
the de novo sphingolipid biogenesis is catalyzed by the serine-palmitoyltransferase 
(SPT) that conjugates palmitoyl-CoA with L-serine. Recently it was shown that SPT 
can also use other amino acids as alternative substrates such as alanine or glycine to a 
certain extent. This forms a class of atypical 1-deoxy-long chain bases (1-deoxy-
LCBs), (Zitomer et al., 2009) that lack the C1-hydroxyl group of the canonical 
substrate sphinganine (C18SA). The conjugation with alanine forms 1-
deoxysphinganine (1-deoxySA) whereas the use of glycine results in 1-
deoxymethylsphinganine. Thus deoxyLCBs can be metabolized to 1-
deoxy(dihydro)ceramides and 1-deoxysphingosine but not further to complex 
sphingolipids nor canonically degraded as the catabolic intermediate sphigosine-1- 
phosphate cannot be formed. In consequence they accumulate and were shown to 
induce cell death in different cells types (Cuadros et al., 2000; Salcedo et al., 2007; 
Sánchez et al., 2008; Zuellig et al., 2013). In isolated dorsal root ganglion neurons a 
neurotoxic effect of deoxyLCBs was highlighted and associated with alterations in 
neurofilament structure and neurite numbers (Penno et al., 2010).  
Hereditary sensory and autosomal neuropathy type 1 (HSNA1) is a dominantly 
inherited axonal neuropathy that is clinically characterized by a progressive loss of 
pain and temperature sensation and possible neuropathic pain attacks and skin ulcers 
(Houlden et al., 2006). HSAN1 is associated with several missense mutations in the 
SPT genes SPTLC1 and SPTLC2. These mutations greatly increase the activity of 
SPT with alanine and glycine and results in a pathologically enhanced deoxyLCB 
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generation which underlies the HSAN1 pathology (Eichler et al., 2009; Gable et al., 
2010; Penno et al., 2010). Elevated plasma levels of deoxyLCBs were also found in 
an HSAN1 mouse model (Eichler et al., 2009).  Clinically, HSAN1 is very similar to 
diabetic sensory neuropathy (DSN), the most common chronic complication in 
diabetes. Recently deoxyLCBs were reported to be elevated in plasma of patients with 
metabolic syndrome and diabetes mellitus type 2 (Bertea et al., 2010; Othman et al., 
2012). This suggests that deoxyLCBs may be novel therapeutic targets for the 
treatment of T2DM and DSN. It is therefore important to get a better insight on the 
mechanisms by which deoxyLCBs mediate their neurotoxic activity. The objective of 
this study was to investigate the impact of 1-deoxySA on cell survival and 
cytoskeletal integrity in cultured neurons and to unravel the underlying molecular 
mechanisms that drive 1-deoxySA-induced cell death and cytoskeletal alterations.  
 
 
Material and Methods 
All experiments were performed in accordance with Swiss animal protection laws and 
University of Zürich institutional guidelines for animal experimentation. 
 
Reagents and Antibodies 
If not stated differently chemicals and reagents were purchased from Sigma-Aldrich 
(Missouri, USA). All cell culture reagents were purchased from Life Technologies 
(Zug, Switzerland). The following antibodies were used: anti Rac1 (BD Biosciences, 
6DQ-RVH&$86$DQWL5KR$DQGDQWLS6DQWD&UX]&$86$DQWLȕ-Actin 
(Sigma), anti TUJ-1 (COVANCE, Berkeley, CA, USA), anti phospho JNK and anti 
total JNK (R&D Systems, Minneapolis, MN, USA), anti NF-H and anti NF-L 
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(NOVUS, Littleton, USA), anti phospho Ezrin (Thr567) and anti total Ezrin, anti 
PSD-95, anti IRSp53, anti MAP2, anti NMDAR2B (all Cell signaling, Danvers, MA, 
USA). InSolution Rac1 inhibitor (Millipore, Billerica, MA, USA), Rho inhibitor 
(Cytoskeleton, Denver, CO, USA), JNK inhibitor SP600125 (Sigma). 
 
Neuronal culture 
Primary neuronal cells were obtained from cerebral cortex of C57Bl/6 mouse 
embryos at gestational stage E14 as described previously (Ogunshola et al., 2002). 
Following dissection cortices were dissociated in Hank`s buffer saline containing 
trypsin and DNaseI for 5 min at 37°C. Cells were seeded on poly-L-lysine coated 
plastic petri dishes or on poly-D-lysine coated glass coverslips in 24 well plates (60 
000 cells/cm2). Neurobasal medium was complemented with B27 supplement (1X), 
AlbuMAXI (0.25g/ml), streptavidin-penicillin (1%), Sodium-Pyruvate 100U/ml and 
L-Glutamine (0.5 mM). Neurons were maintained at normal atmosphere (21% O2, 5% 
CO2) in a humidified incubator at 37 °C for 6 or 17 days (days in vitro=DIV). Half the 
media was replaced every 6 days.  
 
Lipid and inhibitor treatment 
Lipids were synthesized as BSA complex as described in (Penno et al., 2010) and 
added to the cells for 24 or 48 hours. BSA was used as control. Fumonisin B1 and 
inhibitors of Rac1, RhoA and JNK were added 30 min prior cells were exposed to the 
lipids. MK-801 and memantine were added 1h prior lipid treatment.  
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Analysis of sphingoid bases and ceramides by LC±MS/MS  
Ceramide species were extracted by adding 1 ml methanol/chloroform (2:1) 
(including 200 pmole of C12 ceramide or C12 1-deoxydihydroceramide internal 
standards (Avanti Polar Lipids) to 100 µl of re-suspended cells followed by the 
DGGLWLRQRIPORIFKORURIRUPDQGȝODONDOLQHZDWHU,QWHUIHULQJSKRVSKROLSLGV
were hydrolyzed by re-extracting the dried lipids with methanol-KOH:chloroform 
(4:1) as described earlier (Penno 2010). Lipids were separated on a C18 column 
8SWLVSHUH  c ȝP  î  PP ,QWHUFKLP )UDQFH DQG DQDO\]HG RQ D 764
Quantum Ultra (Thermo, Reinach, Switzerland) using atmospheric pressure chemical 
ionization (APCI) (10). Ceramides and 1-deoxydihydroceramides were identified by 
precursor ion scan (20mV collision energy) with fragments of (m/z 264.3) and (m/z 
268.3) respectively 
 
Western Blot 
Neurons were lysed in ice-cold lysis buffer (150 mM NaCl, 50 mM Tris, 1% Triton 
X-100, 1% NP-40) for 10 min and centrifuged at 16 000 rcf for 10 min at 4°C. The 
supernatant was collected and stored at -20°C. Protein concentration was measured 
using Bio-Rad assay (according manufacturers protocol). 40- ȝJ RI SURWHLQZHUH
loaded on SDS-polyacrylamide gels then transferred to nitrocellulose membrane. 
After blocking in 0.1% TBS-Tween with 5% milk powder or 5 % BSA membranes 
were incubated overnight at 4°C with primary antibody. Membranes were washed 
before being incubated with an HRP-conjugated secondary antibody for 1h at room 
temperature. All blots were normalized to TUJ- RU WR ȕ-Actin and quantified by 
densitometry using imageJ software.  
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RNA isolation and PCR Array 
Total neuronal RNA was extracted using TRIzol reagent (Invitrogen, AG, 
Switzerland) according to the manufacturer`s protocol and RNA concentration and 
quality was detected using NanoDrop spectrophotometer (Thermo Scientific, 
Walthman, MA, USA). Equivalent amounts of RNA were used for subsequent cDNA 
synthesis with the RT2 First Strand (SABiosciences). Together with the RT2 qPCR 
Master Mix the obtained cDNA was loaded into each well of the 96-well Mouse 
Cytoskeleton Regulators RT2 Profiler PCR Array System (SABiosciences, 
Hombrechtikon, Switzerland). The PCR was run according to the manufacturer`s 
protocol using an ABI 7500 RT-PCR thermocycler (Applied Biosystems, Foster City, 
CA, USA) and obtained data were analyzed using the Excel template provided by 
6$%LRVFLHQFHVEDVHGRQWKHǻǻ&W-Method. 
 
Immunocytochemistry 
Cells on glass coverslips were fixed for 5 min in 4% paraformaldehyde in PBS, 
permeabilized 3 to 5 minutes with 0.1% Triton X-100 in PBS and then blocked in 
10% normal goat serum.  Antibodies were applied overnight at 4°C. Cells were 
incubated with fluorescent secondary antibody (AlexaFluor488, AlexaFluor594, 
Molecular Probes, Leiden, Netherlands) for 1h at room temperature. After washing 
with PBS cells were counterstained with 10 nM DAPI in H2O for 5 min. For F-actin 
staining cells were incubated in Phalloidin-tetramethylrhodamine for 40 min at room 
temperature after fixation. Coverslips were mounted in fluorescent mounting medium 
(Dako, Glostrup, Denmark) then viewed and analyzed with an Axiovert inverted 
fluorescent microscope (Zeiss, Germany). 
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Rho GTPase activity assay (G-LISA) 
The activation of Rac1 and RhoA was assessed by using the colorimetric G-LISA 
Activation Assay Biochem Kits (BK125, BK124, Cytoskeleton, Denver, CO, USA). 
Briefly lysates were collected, protein concentrations were determined and samples 
were snap-frozen until the assay was prepared. All steps were performed according to 
the manufacturer¶s protocol. 
   
Cell death assays 
1) LDH assay: To quantify cell death the release of lactate dehydrogenase from cells 
into the culture medium was detected using Cytotoxicity Detection Kit (Roche, 
Penzberg, Germany) according to the manufacturer¶s instructions. 
2) MTT assay: Thiazolyl blue tetrazolium bromide was dissolved in PBS and added 
to the cells in a 96 well format (final concentration 0.5 mg/ml). After 1h incubation at 
37°C media was removed and 100 µL dimethyl sulfoxide was added to cells to 
measure absorption at 595 nm (subtract background at 670 nm). 
 
Statistical analysis 
All graphs represent at least 3 independent experiments and analyzed using GraphPad 
Prism software. In all graphs error bars represent the mean ± standard deviation. Data 
were analyzed using one-way or two-way ANOVA and subsequent Bonferroni post-
hoc testing was done. A value of p<0.05 was considered significant with * used to 
designate comparison between the lipid treatments and $ for comparison of inhibitor 
treatments with the lipid-only control within the group. 
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Results 
1-deoxySA is toxic for cortical neurons.  
We first analyzed the effect of 1-deoxysphinganine (1-deoxySA) on the survival of 
cortical neurons. Neurons were cultured for 17 days after isolation and then treated 
for 24h and 48h with either 1-deoxySA, C18SA or C18SO. C18SA and C18SO are 
the canonical LCBs. Since the lipids were complexed to BSA, lipid-free BSA was 
used as control. Cell death was monitored using MTT assay and LDH cytotoxicity 
assays (Fig. 1). The addition 0.5 µM of 1-deoxySA for 24h showed a marked 
decrease of cell survival in the MTT assay (52.7% ± 24.0, p<0.001) compared to 
controls and was significantly further decreased after 48h (15.0% ± 5.7, p<0.001 
versus 24h sample) (Fig. 1A). Higher concentration, 2 µM, of 1-deoxySA induced 
significant cell death already after 24h (6.9% ± 0.1, p<0.0001). No toxic effect was 
seen for C18SO or BSA whereas 2 µM C18SA showed some minor impact on 
survival when added for 48h. (69.4% ± 12.2; p<0.01). A similar picture, although not 
as striking, was seen with the LDH assay (Fig. 1B). At 2 µM 1-deoxySA induced cell 
death by approximately 20% (19.5% ± 9.7, p<0.05) and 30 % (31.7% ± 8.5, p<0.01) 
compared to BSA alone. At 0.5 µM 1-deoxySA induced significant cell death only 
after 48h (17.4% ± 2.3, p<0.05 versus BSA). Neither C18SO nor C18SA had a 
negative effect on cell survival.  
Ceramide is the downstream product of sphinganine and an important signaling 
molecule which was shown to induce cell death in various cell types including 
neurons (Medler et al., 2008; Obeid et al., 1993; Stoica et al., 2005). In analogy also 
1-deoxySA is metabolized further downstream to 1-deoxy(dihydro)ceramide. 
Intracellular ceramide species in 1-deoxySA treated neurons were observed in a 
concentration-dependent accumulation of 1-deoxydihydroceramide which was 
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primarily conjugated with a C18 fatty acid (m18:0,18:0). No 1-
deoxydihydroceramides was seen in C18SA or BSA treated controls (Fig. 1C). 
Normal ceramide levels were not altered by 1-deoxySA-treatment (Supplementary 
figure A).  In parallel to the accumulation of 1-deoxydihydroceramide we observed 
the accumulation of another lipid species that matched the theoretical mass and in 
source fragmentation signature of deoxyceramides. However, the retention time of 
this metabolite was shifted compared to the synthetic standards which is why the 
exact nature of this metabolite was not fully confirmed yet. To investigate whether 
neurotoxicity is mediated by 1-deoxydihydroceramide we blocked its formation by 
inhibiting ceramide synthase with Fumonisin B1 (FB1) at different concentrations. 
Cells were treated with 0.5 µM or 2 µM of 1-deoxySA for 24h and cell survival was 
assessed by MTT (Fig. 1D). Again, 1-deoxySA significantly impaired cell survival in 
a concentration-dependent manner but survival was significantly improved when 
neurons were pretreated with FB1. The survival of cells that were treated with 0.5 µM 
1-deoxySA and 15 µM FB1 was comparable to the controls (96.7% ± 10.0) whereas 
cells treated with 2 µM of 1-deoxySA were rescued by FB1 in a concentration-
dependent manner and showed a survival comparable to controls at 70 µM FB1 
(94.5% ± 12.8). 
Thus 1-deoxySA is internalized by neurons and further metabolized to 
deoxy(dihydro)ceramide species that mediate neurotoxic effects in a concentration 
and time-dependent manner. 
1-deoxySA leads to disruption of cytoskeleton structures. 
It was reported that 1-deoxySA induced alterations in neurofilament structure and loss 
of neurites in cultured sensory neurons (Penno et al., 2010). Therefore we tested the 
effect of 1-deoxySA on the cytoskeleton in our model (Fig. 2). Exposure to 0.5 µM of 
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C18SA or 1-deoxySA for 24h did not alter neurofilament structures, whereas at 2 µM 
we observed a strongly reduced staining for NF-L and NF-H compared to the BSA 
control. BSA and C18SA-treated samples showed a tightly connected neuronal actin 
network whereas 0.5 µM 1-deoxySA was associated with a loss of stained neurites. 
At higher 1-deoxySA-concentrations the intensity of the staining was further reduced. 
At 2 µM 1-deoxySA clearly induced F-actin alterations whereby the neurite structures 
looked less distinct and the staining appeared fuzzy. Similar effects were observed in 
samples that were stained for MAP2, a dendritic microtubule marker. 1-deoxySA 
treated cells showed less neurites and an increasingly punctuated staining. Hence 1-
deoxySA induces alterations in neurofilament, actin and microtubule structures and 
results in the loss of neurites. 
 
1-deoxySA-induced neurotoxicity is associated with decreased Rac1 activity. 
Rho GTPases are not only key players in regulating cytoskeletal organization but can 
also regulate neuronal survival via their downstream cascades. We investigated 
whether inhibition of the Rho GTPases Rac1 and RhoA affects neuronal survival and 
whether Rho GTPase deregulation is associated with 1-deoxySA-induced 
cytoskeleton alterations. Inhibition of RhoA did not alter neuronal survival but 
blocking of Rac1 induced significant cell death (Supplementary figure B.3). We then 
used G-LISA assays to assess activity states of Rac1 and RhoA and indeed observed 
that the activity of both GTPases was reduced in cells treated with 2 µM 1-deoxySA 
(67.1% ± 12.0, p<0.01 and 65.6% ± 26.3 respectively), although RhoA activity results 
did not reach significance. Total levels of both proteins were unchanged 
(Supplementary figure B.1, B.2). One of the downstream targets of Rac1 is JNK, 
which is involved in the regulation of cell survival and cell death. Neuronal JNK 
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activity is strongly dependent on Rac1 (Güntert el al., unpublished) and similarly to 
Rac1 inhibition of JNK significantly impaired neuronal survival (Supplementary 
figure B.3). We thus explored whether 1-deoxySA treatment leads alters JNK activity 
using Western blot (Fig. 3C). Indeed 2 µM 1-deoxySA significantly diminished JNK 
phosphorylation (p<0.01 versus BSA) while total JNK levels remained constant. 
Taken together this data suggest that part of the neurotoxic effects of 1-deoxySA may 
be associated with reduced activation of Rac1 and its downstream target JNK. 
 
1-deoxySA deregulates the cytoskeleton-associated proteins IRSp53 and Ezrin. 
Since 1-deoxySA leads to distinct cytoskeletal changes we hypothesized that 
cytoskeletal regulators other than Rho GTPases could also be modulated by the 
deoxy-lipid. Therefore we used a specific qRT-PCR array to screen for expression of 
84 genes that encode for cytoskeleton regulating proteins comparing cells treated with 
2 µM 1-deoxySA or with 2 µM C18SA. We observed significant changes in 
expression of predominantly 6 genes (Supplementary figure C). Interestingly the 
expression of baiap2 was 3.64 fold higher in 1-deoxySA-treated cells. This gene 
encodes for insulin receptor substrate 53 (IRSp53), a downstream target of Rho 
GTPases and part of a protein complex with postsynaptic density protein 95 (PSD-95) 
and N-methyl-D-aspartate receptor (NMDAR) that is involved in synaptogenesis and 
dendritic spine morphogenesis (Choi et al., 2005). Immunocytochemistry in contrast 
to RNA levels showed 1-deoxySA decreased IRSp53-specific staining compared to 
C18SA and BSA-treatment (Fig. 4A). Western blot analysis of cells pre-incubated 
with the NMDAR antagonists MK-801 and memantine (10 µM for 1h) in addition to 
the lipid treatment was used to confirm involvement of NMDAR in 1-deoxySA-
induced neurotoxicity. Consistent with the staining we found that the presence of 2 
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µM 1-deoxySA reduced IRSp53 protein levels by 60 % (41.9% ± 11.9, p<0.05) 
compared to controls (Fig. 4B). Interestingly both NMDAR inhibitors could reverse 
this effect (Mema: 80.2% ± 32.2; MK-801: 89.7% ± 25.2, p<0.05 versus 2 µM 1-
deoxySA only) suggesting a role for NMDAR in 1-deoxySA-induced toxicity. 
The qRT-PCR panel also indicated a 2.61 fold upregulation of Erzin, a cytoplasmic 
peripheral membrane protein belonging to the ERM protein family. Ezrin links the 
plasma membrane with the actin cytoskeleton and is involved in adhesion, membrane 
ruffling and microvilli formation (Tsukita, 1999). Phosphorylation of Ezrin has been 
shown to be involved in cytoskeletal rearrangements (Belkina et al., 2009). Similar to 
IRSp53 we performed immunocytochemistry for Ezrin and analyzed phosphorylated 
as well as total protein levels (Fig. 4C). We detected elevated phospho-ezrin staining 
in 1-deoxySA-treated cells compared to controls. An enhanced phospho/total Ezrin 
ratio was confirmed by Western blot in 2 µM 1-deoxySA-treated neurons (174.5% ± 
20.3, p<0.05) whereas total Ezrin levels remained stable (Fig. 4D). Similar to IRSp53, 
blocking the NMDAR with MK-801 and memantine significantly prevented the 1-
deoxySA-induced changes (p<0.05 and p<0.01, respectively). 
In summary 2 µM 1-deoxySA deregulates the cytoskeleton-associated proteins 
IRSp53 and Ezrin on both protein and expression level in cortical neurons that can be 
prevented by inhibition of NMDAR. 
 
1-deoxySA decreases protein levels of NMDAR NR2B subunit and the 
NMDAR-associated protein PSD95.  
Since the effects of 1-deoxySA on cytoskeletal proteins could be reversed by 
NMDAR inhibition we evaluated if the lipid directly influences NMDAR. Using 
qRT-PCR we detected a high expression of NMDA receptor subunits NR2B and NR1 
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NMDAR (data not shown). We selected NR2B subunit for further analysis since it 
connects with PSD-95 (Kornau et al., 1995) that in turn forms a complex with IRSp53 
(Choi et al., 2005). Like before we treated neurons with BSA, C18SA, 1-deoxySA 
with or without MK-801 or memantine and detected NR2B by Western blot (Fig. 5A).  
The presence of 2 µM 1-deoxySA resulted in a significant loss of NR2B protein 
(23.6% ± 8.8, p<0.01) compared to C18SA or BSA treated cells. Again pre-
incubation with both NMDAR inhibitors significantly prevented the 1-deoxySA-
induced effect. MK-801 recovered NR2B levels to more than 80% (82.9% ± 15.2, 
p<0.01 versus 2 µM 1-deoxySA) and memantine elevated it to 75% (73.0% ± 11.2, 
p<0.05 versus 2 µM 1-deoxySA). As expected the effect of 1-deoxySA on PSD-95 
was very similar to NR2B. The presence of 2 µM 1-deoxySA led to a strong decrease 
of PSD-95 protein levels (p<0.05) compared to BSA (Fig. 5B). However inhibition of 
NMDAR could only partly prevent the reduction in PSD-95 levels and did not reach 
significance.  
 
NMDAR inhibition reduces 1-deoxySA-induced cleavage of p35 to p25 and 
neurotoxicity. 
It has been shown that in hippocampal neurons NMDAR activation can induce 
cleavage of the CDK5-activator p35 (Kerokoski et al., 2004). The cleavage of p35 to 
p25 and the subsequent deregulation of CDK5 is associated with neurodegeneration 
and cytoskeletal abnormalities (Lee et al., 2000; Patrick et al., 1999). Next we 
investigated if 1-deoxySA induces cleavage of p35 and if this can be prevented by 
NMDAR inhibition. Furthermore we tested if blocking the NMDAR can prevent 1-
deoxySA-induced neuronal death. The presence of 2 µM 1-deoxySA reduced p35 
protein levels by more than 60 % (p<0.0001) compared to BSA. Both NMDAR 
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antagonists could prevent this decline although the pretreatment with memantine did 
not reach significance (Fig. 6A). Accordingly 2 µM of 1-deoxySA induced a strong 
accumulation of p25 (443.6% ± 58.9, p<0.0001) that, again, could be significantly 
reduced by a pre-treatment with both MK-801 and memantine (141.1% ± 13.1, 
p<0.001 and 261.5% ± 70.3, p<0.01 versus 2 µM 1-deoxySA, respectively); (Fig.6B). 
The influence of the NMDAR antagonists on cell survival was assessed by LDH (Fig. 
6C) and MTT assay (Fig. 6D). The LDH assay showed that pretreatment with both 
MK-801 and memantine could significantly reduce 1-deoxySA-induced cell death 
(p<0.0001). The same tendency was observed in the MTT assay (Fig. 7D) although 
the effects were not as pronounced. Both MK-801 and memantine-pretreated cells 
showed an increased survival compared to 1-deoxySA-treatment in the absence of the 
inhibitors (21.6% ± 1.8 and 22.9% ± 4.0, both p<0.0001) although survival was still 
reduced compared to BSA-treated controls. Additional brightfield images also 
showed the effect of NMDAR antagonists on cell morphology (Supplementary figure 
D). 
In conclusion, 1-deoxySA induces cleavage of p35 and accumulation of p25, both of 
which can be strongly reversed by NMDAR antagonists. In addition 1-deoxySA-
mediated neuronal death can be partly reversed by NMDAR inhibition. 
 
 
Discussion 
Deoxy-long chain bases are neurotoxic lipids involved in the pathology of HSAN1 
and may also contribute to the progression of T2DM and DSN. HSAN1 and DSN are 
clinically similar and both associated with increased deoxyLCB formation (Bertea et 
al., 2010; Othman et al., 2012; Zuellig et al., 2013). Since the mechanisms of 
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deoxyLCBs-mediated neurotoxicity are largely unknown we aimed to elucidate the 
effects of 1-deoxySA on cultured neurons. We show that 1-deoxySA-induced 
neuronal death is mediated by deoxy-ceramide species and identified several 
cytoskeleton-associated factors that are modulated by 1-deoxySA. Moreover we 
demonstrated that 1-deoxySA modulates NMDAR subunit NR2B and inhibition of 
NMDAR activation greatly prevented 1-deoxySA-induced neuronal death. Based on 
these finding we propose a model of how 1-deoxySA might mediate neurotoxicity 
(Fig 7). 
It has been shown previously that deoxysphingolipids induce cell death in different 
cells types (Cuadros et al., 2000; Salcedo et al., 2007; Sánchez et al., 2008; Zuellig et 
al., 2013). Similarly we observed a time and concentration dependent neurotoxic 
effect of 1-deoxySA on primary cortical neurons. Internalization and further 
metabolism of 1-deoxSA to deoxyceramide species appeared to be responsible for the 
observed toxicity since the inhibition of ceramide synthase rescued neurons from cell 
death. Similar results were recently reported in pancreatic ȕ-cells suggesting a more 
general mode of action of deoxyLCBs (Zuellig et al., 2013). However, ceramide 
synthesis is essential and FB1 is toxic in vivo [see for review (Stockmann-Juvala and 
Savolainen, 2008)] and genetic deletion of ceramide synthase has been shown to 
results in detrimental phenotypes (Imgrund et al., 2009; Pewzner-Jung et al., 2010; 
Silva et al., 2012). Thus inhibition of ceramide synthase cannot be considered as 
therapeutic approach to prevent 1-deoxySA-induced toxicity.  
In response to 1-deoxySA we observed structural alteration for all three cytoskeleton 
components, actin filaments, neurofilaments and microtubules in cultured neurons. 
Indeed 1-deoxySA induced actin rearrangements in insulin-producing cells (Zuellig et 
al., 2013) and the disassembly of stress fibers in Vero cells has been reported 
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previously (Cuadros et al., 2000). In contrast to our data these studies did not report 
alterations in microtubule structures indicating that the potential of 1-deoxySA to 
affect microtubules might be neuron-specific. Indeed, gene expression for CLIP1 was 
5 fold reduced in 1-deoxySA treated neurons compared to control. CLIP1 controls 
microtubule growth and bundling and utilizes Rac1 to bind to microtubules (Arnal et 
al., 2004; Fukata et al., 2002; Nakano et al., 2010). Although CLIP1 was not further 
analyzed in this work disruption/reduction of its function might also contribute to 
altered neuronal microtubule structures upon 1-deoxySA-treatment. The lipid-induced 
cytoskeletal alterations are unlikely a consequence of neuronal death but rather a 
direct effect of 1-deoxySA that might contribute to cell death. Indeed it was shown 
earlier that 1-deoxySA at concentrations of up to 1 µM were not directly cytotoxic to 
cultured dorsal root ganglion neurons despite induced neurofilaments retraction and 
disturbed actin-neurofilament interactions (Penno et al., 2010). Similarly, 1-deoxySA 
induced alterations in pancreatic beta-cells before apoptotic markers were upregulated 
(Zuellig et al., 2013). ! Notably, cytoskeleton alterations, especially impaired axonal 
transport, have been described for DSN (McLean, 1997). Furthermore Medori and 
colleagues demonstrate impairment of axonal transport of neurofilament, actin and 
tubulin and described distal axonal atrophy accompanied by a great loss of 
neurofilaments in a rat diabetes model (Medori et al., 1985, 1988). Hence 1-deoxySA-
treatment induces cytoskeleton alterations very similar to those described in 
peripheral neuropathies, thus confirming the usefulness of our model system. 
Rho GTPases have been proposed to be involved in lipid-induced cytoskeleton 
rearrangements (Cuadros et al., 2000). Our data suggest that a significantly reduced 
Rac1 activity underlies 1-deoxySA-induced cytoskeletal rearrangements. A cell-type 
specific regulation seems evident since earlier data from beta cells showed that 1-
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deoxySA increased Rac1 activity and actin accumulation whereas we observed a 
disassembly of neuronal microfilaments together with decreased in Rac1 activity. 
JNK, a general downstream target of Rac1 (Minden et al., 1995) is also in our own 
neuronal model highly dependent on Rac1 (Güntert et al. unpublished). Thus we 
suggest that 1-deoxySA triggers JNK inactivation via the inactivation of Rac1 
correlating with the fact that inhibition of both has negative effects on neuronal 
survival. This agrees with studies by Le and colleagues (Le et al., 2005) that 
demonstrated that Rac1 inhibition triggers apoptosis in cerebellar granule neurons. In 
contrast other studies report that JNK inhibition is beneficial for the survival of 
cerebellar granule neurons and beta cells (Bonny et al., 2001; Mei et al., 2008). 
However in BCR/ABL-transformed leukemic cells and B-lymphoma cells JNK 
promoted survival (Gururajan et al., 2005; Hess et al., 2002). Moreover it was 
demonstrated that JNK is crucial for interleukin-3 induced survival through 
phosphorylation and thus inactivation of the pro-apoptotic protein BAD (Yu et al., 
2004). Thus the role of JNK in cell death and survival remains controversial and may 
be highly dependent on cell type and stimulus. In our model 1-deoxySA-induced 
reduction of Rac1 activity and the subsequent lowered activity of its downstream 
target JNK might contribute to the observed neuronal death. 
In addition to Rho GTPases, deregulation of Ezrin via 1-deoxySA-triggered 
phosphorylation might contribute directly or indirectly to cytoskeleton 
rearrangements. It has been shown that phospho-Ezrin links the actin cytoskeleton to 
the plasma membrane and interacts with integral membrane proteins to participate in 
signaling processes (Neish and Fehon, 2011). Interestingly Yang and colleagues 
(Yang and Hinds, 2006) demonstrated that CDK5 phosphorylates Ezrin that in turn 
inhibits Rac1 in senescent cells. We also observed p25 accumulation in 1-deoxySA-
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treated cells suggesting a hyperactivation of CDK5. Thus we speculate that CDK5 
may increase Ezrin phosphorylation and thereby suppress Rac1 activity, although 
further studies on this are required. Another protein that seems to be involved in 1-
deoxySA-induced cytoskeletal alterations is IRSp53. IRSp53 forms a complex with 
Rac1 and Wave2 to promote membrane ruffling and dendritic spine morphogenesis. 
(Choi et al., 2005; Miki et al., 2000). Since the formation of the 
Rac1/IRSp53/WAVE2 complex is dependent on Rac1 activity, lipid-induced 
reduction of Rac1 activity may lead to a disruption of this pathway. 
IRSp53 is highly abundant in the postsynaptic density (PSD) where it is associated 
with other signaling partners via scaffolding proteins (Abbott et al., 1999; Bockmann 
et al., 2002; Soltau et al., 2004). One of those signaling partners is PSD-95 that in turn 
interacts with the NMDA receptor, both having a very similar expression pattern 
(Kornau et al., 1995). Indeed, our data demonstrate comparable effects on IRSP53, 
PSD-95 and NMDA receptor subunit NR2B since all proteins were strongly 
decreased in 1-deoxySA-treated neurons. NMDAR degradation is dependent on its 
activity (Kato et al., 2005) and inhibition of the NMDAR prevented 1-deoxySA-
induced loss of NR2B, IRSp53 and to a lesser extent the decrease of PSD-95 levels. 
Thus activation of the NMDAR signaling cascades could mediate the 1-deoxySA 
induced effects. The overactivation of NMDA and AMPA glutamate receptors leads 
to excitotoxicity via increased intracellular calcium and the subsequent cleavage of 
the CDK5-activator p35 to p25 in hippocampal neurons (Kerokoski et al., 2004), an 
outcome tightly associated with neurodegeneration (Lee et al., 2000; Patrick et al., 
1999). Accordingly we noted decreased p35 levels and strong p25 accumulation in 1-
deoxySA-treated neurons that again could be reversed by NMDAR inhibition. This 
suggests that 1-deoxySA-induced neurotoxicity is at least partly mediated by NMDA 
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receptor however further investigations need to elucidate whether 1-deoxySA or its 
further metabolites can directly interact with the receptor. Since AMPA receptor 
activation may also mediate part of the neurotoxic effects of 1-deoxySA it remains to 
be tested whether parallel inhibition of both glutamate receptors could completely 
prevent the cytoskeleton alterations and protect neurons from deoxysphingolipid-
induced death. Notably, both NMDA and AMPA receptors are also expressed in the 
peripheral nervous system (Gangadharan et al., 2011; Ma and Hargreaves, 2000; 
McRoberts et al., 2001) further supporting the validity of our study. Overall a 
multifaceted impact of 1-deoxySA on the cytoskeleton, cytoskeleton regulators and 
associated proteins contributes to neuronal death. 
In conclusion this study underlines various intracellular factors that are modulated by 
1-deoxySA. 1-deoxySA-treatment induces massive changes in neuronal cytoskeleton 
organization and deregulation of a number of cytoskeleton regulating proteins like 
Rac1, Ezrin and IRSp53. Furthermore 1-deoxySA-induced neuronal death is mediated 
by NMDAR NR2B signaling and can be partly prevented by NMDAR antagonists. 
Thus we show for the first time a molecular mechanism by which 1-
deoxysphingolipids can induce neurotoxicity. We therefore hypothesize that 
glutamate receptors may be a potential therapeutic target to prevent 
deoxysphingolipid induced neurodegeneration.  
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Figure legends 
Figure 1: 1-deoxySA and further metabolites are toxic for cortical neurons. 
Neurons were incubated with 0.5 µM or 2 µM of 1-deoxySA, C18SA or C18SO or 
BSA control for 24h or 48h and cell death was assessed by two methods. A, MTT 
assay was used to detect enzymatic activity and BSA was set to 100 %. ** p<0.01 
versus C18SO and BSA, *** p< 0.001 versus 0.5 µM C18SA, C18SO and BSA, **** 
p<0.0001 versus all other treatments. B, LDH assay was applied to detect cytotoxicity 
and BSA was set to 0%. * p<0.05 versus BSA, ** p<0.01 versus C18SA and C18SO, 
*** p<0.001 versus BSA. C, Mass spectrometric quantification shows the elevated 
intracellular 1-deoxy-dh-ceramide levels of different acyl chain length in neurons 
upon treatment with 0.5 µM or 2 µM of 1-deoxySA for 24h compared with 2 µM 
C18SA or BSA as control. Levels (pmol) were normalized to protein content of the 
used cell pellets. * p<0.05, **** p<0.0001 versus BSA and C18SA. Analysis was 
done using one-way ANOVA followed by Bonferroni post-hoc test. D, To inhibit 
ceramide synthesis neurons were exposed to 0.5 and 2 µM 1-deoxySA after 
pretreatment for 30 min with different concentrations of Fumonisine B1 (FB1) and 
cell survival was detected by MTT assay. BSA was used as control and set to 100%. $ 
p<0.01, $$ p<0.001, $$$ p<0.0001 versus control of the same group (0 µM 
Fumonisine B1). Data were analyzed using two-way ANOVA followed by Bonferroni 
post-hoc test.  
 
Figure 2: 1-deoxySA leads to disruption of cytoskeleton structures. 
Cells were treated with 0.5 and 2 µM C18SA or 1-deoxySA or with the BSA control 
for 24h prior to immunocytochemistry. We used anti Neurofilament light (NF-L) and 
anti Neurofilament heavy (NF-H) antibodies to stain neurites. Phalloidin staining was 
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used to visualize filamentous Actin (F-Actin) and anti MAP2 antibody was used as 
microtubule marker. Nuclei were counterstained with DAPI (blue). Scale bar: 50 µM.  
 
Figure 3: 1-deoxySA-induced neurotoxicity is associated with decreased Rac1 
activity.  
Neurons were incubated for 24h with 0.5 µM and 2 µM 1-deoxSA or C18SA or with 
BSA as a control and Rho GTPase activity was determined in cell lysates via A) Rac 
G-LISA and B) RhoA G-LISA to determine Rho GTPase activity. **  p<0.01 versus 
all other treatments. C, Western blot of the lipid-treated neurons was performed to 
detect JNK phosphorylation status. Results are expressed as the ratio of 
phosphorylated (pJNK) versus total protein and were compared to the BSA control. * 
p<0.05 versus C18SO, 0.5 µM 1-deoxySA and 2 µM C18SA, ** p<0.01 versus BSA.  
Data were analyzed using two-way ANOVA followed by Bonferroni post-hoc test. 
 
Figure 4: 1-deoxySA deregulates the cytoskeleton-associated proteins IRSp53 
and Ezrin.  
To determine the effect of exposure to 1-deoxySA, C18SA or BSA on cytoskeleton 
regulating proteins neurons were treated as previously and subjected to 
immunocytochemistry to visualize IRSp53 (A, green) and E(C, green). Scale bar: 50 
µM. B and D, To confirm the staining lipid-treated neurons were used for Western 
blot to detect IRSp53 (B) and the phosphorylated and total form of Ezrin (D). In 
addition to 1-deoxySA exposure cells were pre-incubated for 1h with 10 µM of the 
NMDAR inhibitors MK-801 or Memantine (Mema).* p<0.05 versus C18SA and 
BSA, $ p<0.05 versus 2 µM 1-deoxySA (B). D, To assess changes in Ezrin 
phosphorylation the result are displayed as ratio between the phosphorylated (p-Ezrin) 
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and the total protein form and compared to BSA. * p<0.05 versus C18SA and BSA, $ 
p<0.05 and $$ p<0.01 versus 2 µM 1-deoxySA. Data were analyzed using two-way 
ANOVA. For comparison between MK-801 and memantine with 1-deoxySA only 
one-way ANOVA was applied. Both analyses were followed by Bonferroni post-hoc 
test. 
 
Figure 5: 1-deoxySA decreases protein levels of NMDAR NR2B subunit and 
the NMDAR-associated protein PSD95. 
To determine the effect of lipid treatment on NMDAR and PSD-95 neurons were 
treated with 1-deoxySA, C18SA or BSA in the presence or absence of 10 µM of the 
NMDAR inhibitors MK-801 and memantine (Mema). Lysates were loaded on 
polyacrylamide gels and NR2B (A) and PSD95 (B) were detected by Western blot.  
A, Western blot for NR2B. ** p<0.01 versus BSA, C18SA and 0.5 µM 1-deoxySA, $ 
p<0.05 and $$ p<0.01 versus 2 µM 1-deoxySA. B, Western blot for PSD-95. * 
p<0.05 versus BSA ** p<0.01 versus C18SA. Data were analyzed using two-way 
ANOVA. For comparison between MK-801 and memantine with 1-deoxySA only 
one-way ANOVA was applied. Both analyses were followed by Bonferroni post-hoc 
test. 
 
Figure 6: NMDAR inhibition reduces 1-deoxySA-induced cleavage of p35 to 
p25 and neurotoxicity.  
As previously cells were exposed to 1-deoxySA, C18SA or BSA in the presence or 
absence of MK-801 and memantine to detect effects on p35 and p25 levels and on cell 
survival. A,B, Western blot was performed to detect p35 and p25 protein levels using 
an antibody that detects both of the proteins. A, The graph shows p35 levels. *** 
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p<0.001 versus 0.5 µM 1-deoxySA, **** p<0.0001 versus BSA and C18SA, $$ 
p<0.01 versus 2 µM 1-deoxySA. B, The graph shows p25 levels. * p<0.05, ** p<0.01 
versus BSA, *** p<0.001 versus 2 µM C18SA, **** p< 0.0001 versus BSA, $$ 
p<0.01 and $$$ p<0.001 versus 2 µM 1-deoxySA. The effect of lipid treatment and 
NMDAR inhibition on cell survival was determined using LDH (C) and MTT assay 
(D). C, Cytotoxicity was detected by measuring LDH in the supernatant. BSA control 
was set to baseline. *** p<0.001 versus 0.5 µM 1-deoxySA, **** p<0.0001 versus 
BSA and C18SA, $$$$ p<0.0001 versus 2 µM 1-deoxySA. D, MTT assay was as 
measurement for cell survival and BSA control was set to 100%. **** p<0.0001 
versus BSA, C18SA and versus 0.5 µM and 2 µM 1-deoxySA respectively, $$$$ 
p<0.0001 versus 2 µM 1-deoxySA. Data were analyzed using two-way ANOVA. For 
comparison between MK-801 and memantine with 1-deoxySA only one-way 
ANOVA was applied. Both analyses were followed by Bonferroni post-hoc test. 
 
Figure 7: Possible mechanism of 1-deoxySA-induced neurotoxicity  
Schematic representation of our results.  
 
 
Supplementary figure A: 1-deoxySA does not alter intracellular ceramide 
levels.  
Mass spectrometric quantification of intracellular ceramides of neurons treated for 
24h with 0.5 µM or 2 µM of 1-deoxySA, or with 2 µM C18SA or BSA as control. 
Ceramide levels (pmol) were normalized to protein content of the used cell pellets.  
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Supplementary figure B: 1-deoxySA does not alter total Rac1 or total RhoA 
levels. 
Neurons were incubated for 24h with 0.5 µM and 2 µM 1-deoxySA, C18SA or 
C18SO or with BSA as a control and Western blot was performed to detect Rac1 (A) 
and RhoA (B) with specific antibodies. C, To determine the effect of Rac1, RhoA and 
JNK inhibition on neuronal survival MTT assay was performed on neurons pretreated 
with 100 µM of Rac1 or Rho inhibitor (Rac1/Rho inhib) or with 50 µM of SP600125 
(SP) for 30 min prior to lipid incubation as above. **** p<0.0001 versus BSA and 
Rho inhib. Data were analyzed using one-way ANOVA followed by Bonferroni post-
hoc test. 
 
Supplementary figure C: Cytoskeleton regulator qPCR array. 
RNA was extracted from cells treated with 2 µM 1-deoxySA or C18SA for 24h and 
cDNA was synthesized using an array compatible kit. Together with the compatible 
qPCR master mix the obtained cDNA was added to each well of the Mouse 
Cytoskeleton Regulator RT2 Profiler PCR array plates and analyzed. The table shows 
the three highest fold up and down regulations of 1-deoxySA-exposed cells versus 
C18SA. Baiap2 encoding for insulin receptor substrate p53 (IRSp53) and Ezr for 
Ezrin were selected for further analysis. 
 
Supplementary figure D: Effect of 1-deoxySA-exposure and NMDAR 
antagonist treatment on cell morphology. 
To monitor the effect of 2 µM 1-deoxySA in the presence or absence of 10 µM MK-
801 or memantine (Mema) on cell morphology and survival compared to BSA and 
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C18SA controls we took photographs of our neuronal culture after 24h lipid exposure. 
Scale bar: 50 µM. 
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Abstract 
Irreversible failure of pancreatic !-cells is the main culprit in the pathophysiology of diabetes 
mellitus, a disease that is now a major global epidemic. Recently, elevated plasma levels of 
deoxysphingolipids, including 1-deoxysphinganine, have been identified as novel biomarkers for 
the disease. In this study, we analyzed whether deoxysphingolipids directly compromise the 
functionality of insulin-producing Ins-1 cells and primary islets. Treatment with 1-
deoxysphinganine induced dose-dependent cytotoxicity with senescent, necrotic and apoptotic 
characteristics and compromised glucose-stimulated insulin secretion. In addition, 1-
deoxysphinganine altered cytoskeleton dynamics, resulting in intracellular accumulation of 
filamentous actin and activation of the RhoGTPase Rac1.  Moreover, 1-deoxysphinganine 
selectively up-regulated ceramide synthase 5 expression and was converted to 1-deoxy-
dihydroceramides, without altering normal ceramide levels. Inhibition of intracellular 1-
deoxysphinganine trafficking and ceramide synthesis improved the viability of the cells, 
indicating that the intracellular metabolites of 1-deoxysphinganine contribute to its cytotoxicity. 
Analyses of signaling pathways identified JNK and p38 MAPK as antagonistic effectors of 
cellular senescence. Our results revealed that 1-deoxysphinganine is a cytotoxic lipid for insulin-
producing cells, suggesting that the increased levels of this sphingolipid observed in diabetic 
patients may contribute to the reduced functionality of pancreatic !-cells. Thus, targeting deoxy-
sphingolipid synthesis may complement the currently available therapies of diabetes. 
 
Page 2 of 45Diabetes
;'(#/0$.L,/!
!NgM!
!!!!!!!!!!!
  
Introduction 
In the last three decades, the prevalence of diabetes has been rising worldwide at a dramatic rate, 
with incidence projections approaching 8% of the population by 2030 (1; 2). This remarkable 
increase is largely due to the epidemic spreading of type 2 diabetes mellitus (T2DM), which 
accounts for 90% of all cases of diabetes mellitus worldwide (reviewed in (3; 4)). Given the level 
of complexity associated with the pathophysiology of T2DM, understanding the mechanisms 
underlying this disease is necessary to design alternative strategies to limit its progression. 
Recently, substantial improvements occurred in the detection of early stage or undiagnosed 
T2DM, thus allowing appropriate treatments in high risk populations. One of the latest 
biomarkers identified in patients with diabetes and metabolic syndromes are increased plasma 
levels of deoxy-sphingolipids (1-deoxySLs) (5; 6), a type of sphingolipid characterized by an 
initial condensation of alanine or glycine instead of serine with palmitic acid and the resultant 
absence of the hydroxyl group in position C1. Consequently, although these deoxy-sphingoid 
bases can be acylated to deoxy-dihydroceramides, they cannot be further metabolized to complex 
sphingolipids or efficiently degraded by the canonical degradation pathway, and thus tend to 
accumulate once produced. Importantly, 1-deoxySLs display toxic properties in vitro toward 
several cell lines (7-9) and in vivo are thought to impair neuronal functionality in patients with 
the hereditary sensory and autonomic neuropathy type I (HSAN1) (10). 
In light of the increased plasma levels of 1-deoxySLs  found in diabetic patients and of the 
reported cytotoxic effects associated with the exposure to increased 1-deoxySL concentrations, 
we investigated whether these atypical sphingolipids directly compromise pancreatic !-cells, the 
dysfunction of which plays an important role in the pathogenesis of both type 1 and type 2 
diabetes. 
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Research Design and Methods  
Biochemical reagents 
Unless otherwise stated, all chemicals were purchased from Sigma and cell culture reagents from 
Gibco-BRL. Inhibitor stock solutions were freshly diluted to the concentrations required for the 
individual experiment indicated in the figure legends. Lipid stock solutions were prepared as a 
bovine serum albumin (BSA) complex, as described in (10), and added to the cells at the 
concentrations indicated in the figure legends. BSA was used as control. 
In vitro cell culture 
The Ins-1 rat insulinoma cell clone 832/13, generously provided by C. Wollheim, was maintained 
in RPMI 1640 medium, as described (11; 12). Cell metabolic activity was tested with 0.5% 
tetrazolium salt solution 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), or 
WST-1 (Roche), according to the manufacturer’s instructions. Cell death was quantified by 
trypan blue exclusion or lactate dehydrogenase (LDH) release in the medium (Roche). Cellular 
senescence was quantified with the !-galactosidase assay kit (Cell Biolabs). Adp21 (rat) and 
AdGFP adenovirus were purchased from Vector Biolabs, Philadelphia, USA. Rac1 activity was 
measured with G-LISA Rac1 activation assay (Cytoskeleton, Denver, USA). 
Animal experiments 
Wistar rats, leptin deficient ob/ob mice on C57BL/6J background (B6.V-Lep/OlaHsd) and wild 
type (WT) C57BL/6J (Harlan Laboratories) were kept under a light-dark regime (16:8 h), 
constant temperature, and free access to food and water. All animal experiments were performed 
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in accordance with swiss federal animal regulations and approved by the cantonal veterinary 
office of Zurich. 
Islets were harvested from pancreata of male Wistar rats (250 to 300 g) by collagenase (NB8 
collagenase, Serva, Heidelberg, Germany) followed by trypsin digestion to dissociate them into 
single cells, according to (13).  
Insulin secretion 
Dissociated islets cells were seeded in 12-well ECM coated plates (Novamed, Jerusalem, Israel), 
treated for 24 h with 5 !M sphinganine, 1-deoxysphinganine or BSA and incubated in RPMI 
medium containing 3.3 mM glucose for 1 h. Following sequential 1 h incubations with low (3.3 
mM), high (16.7 mM), low (3.3 mM) glucose concentrations, insulin secretion was measured by 
radioimmunoassay (Insulin-CT, CIS, Biointernational, Schering AG, Baar, Switzerland), 
according to the manufacturer’s instructions. 
qRT-PCR  
Total RNA was extracted from Ins-1 cells cultured in 1 !M sphinganine or 1-deoxysphinganine 
for 24 h. Quality of RNA was assessed by 2100 bioanalyzer (Agilent Technologies, Basel, 
Switzerland). cDNA was obtained with the RT2 First Strand Kit and profiled using the Rat Cell 
Death Pathway Finder PCR Array  (both from SABiosciences, Hombrechtikon, Switzerland), 
according to the manufacturer’s instructions. CerS primers for SYBR green qPCR are listed in 
Supplementary Materials and Methods. 
Immunohistochemistry and flow cytometry analyses 
Pancreas specimens were fixed in 4% formalin and paraffin embedded according to standard 
procedures (14). Ins-1 cells were fixed in 3.6% formaldehyde and permeabilized with 0.2% 
Triton X-100 in PBS. Primary antibodies used in this study are listed in Supplementary Materials 
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and Methods. Apoptosis detection was performed with an ApopTag peroxidase Kit (MP 
Biomedicals, Illkirch, France). Immunofluorescence analysis and image data collection were 
performed on a Zeiss Axioplan 2 Imaging fluorescence microscope (Carl Zeiss Microimaging, 
Göttingen, Germany), or on a Leica SP2 AOBS confocal laser-scanning microscope (Leica 
Microsystems, Wetzlar, Germany) using a glycerol immersion objective lens (Leica, HCX PL 
APO CS 63x 1.3 Corr). Image z-stacks were collected with a pinhole setting of Airy 1 and 
twofold oversampling. Image stacks of optical sections were processed using the Huygens 
deconvolution software package version 2.7 (Scientific Volume Imaging, Hilversum, NL). Three-
dimensional reconstruction, volume rendering, and quantification of signal overlap in the 3D 
volume model were done with the Imaris software suite (Version 7.2.1, Bitplane, Zurich, 
Switzerland). The degree of signal overlap in the 3D volume models is shown graphically as 
scatterplots by plotting the intensity of two fluorescent signals in each voxel of the 3D model. 
Voxels with similar signal intensity for both signals appear in the area of the diagonal.  
Single-cell quantification of stained cells by flow cytometry was performed using a FACSDiva 
flow cytometer (BD Bioscences, Allschwil, Switzerland). 
Western blotting 
Ins-1 cells cultured in 1 !M sphinganine, 1-deoxysphinganine or BSA for 24 h were lysed as 
described (15). Aliquots corresponding to 35 !g of proteins were separated by SDS-PAGE 
electrophoresis, blotted and probed over night at 4°C. Primary antibodies used in this study are 
listed in Supplementary Materials and Methods. Immunoreactive bands from at least 3 
independent experiments were quantified by densitometry and normalized to "-actin or GAPDH 
levels.  
Analysis of sphingoid bases and ceramides by LC–MS/MS 
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The sphingoid base profile was analyzed as described earlier (5). Ceramide species were 
extracted by adding 1 ml methanol/chloroform (2:1) (including 200 pmole of C12 ceramide 
internal standard (Avanti Polar Lipids) to 100 !l of re-suspended cells followed by the addition 
of 0.5 ml of chloroform and 200 µl alkaline water (10). Interfering phospholipids were 
hydrolyzed by re-extracting the dried lipids with methanol-KOH:chloroform (4:1) as described 
earlier (10). Lipids were separated on a C18 column (Uptispere 120 Å, 5µm, 125 × 2 mm, 
Interchim, France) and analyzed on a TSQ Quantum Ultra (Thermo, Reinach, Switzerland) using 
atmospheric pressure chemical ionization (APCI) (10). Ceramides and deoxy-Ceramides were 
identified by precursor ion scan (20mV collision energy) with fragments of (m/z 264.3) and (m/z 
268.3) respectively. Levels were normalized to ISTD and cell numbers.  
Statistical analyses 
Results are expressed as means ± SEM. Significance was assessed using Student’s unpaired, two-
tailed t tests or one-way analysis of variance. A probability value <0.05 was considered 
significant. When the overall probability value was <0.05, the Bonferroni multiple-comparison 
test was used to determine whether there was a significant difference between values of control 
(reference sample) and samples of interest.  
Results 
1-deoxySL treatment is cytostatic and cytotoxic for Ins-1 cells 
As 1-deoxySLs were found elevated in the plasma of diabetic patients in the low !M range (5; 6), 
we analyzed whether 1-deoxySLs can directly affect the viability of insulin-secreting cells. To 
this aim, the rat insulinoma cell line Ins-1 was treated at 50% confluence (Fig. 1A, L: low 
density) for 24 h with 1-deoxysphinganine or sphinganine as control. 1-deoxysphinganine 
incubation reduced both the metabolic activity, as measured by MTT (Fig.1A) and WST-1 
Page 7 of 45 Diabetes
;'(#/0$.L,/!
!NgS!
!!!!!!!!!!!
reduction (Fig. S1A), and the number of live cells (Fig.1B) in a dose-dependent manner. 
Treatment with 5 !M caused cell round up (Fig. 1C) and death, as shown by robust trypan blue 
inclusion (Fig.1D) and LDH release (Fig.1E). However, cells treated with 1 !M 1-
deoxysphinganine did not increase in number compared with the initial seeding but showed 
modest levels of lethality (Fig.1D, E), or up-regulation of genes involved in cell death pathways 
(Fig. S1B-D), suggestive of a cytostatic effect of the lipid at this concentration (Fig. 1B). When 
the lipid treatment was performed on 90% confluent cells (Fig. 1A, H: high density), the 
metabolic activity was reduced only at the highest concentration of 1-deoxysphinganine tested, 
further indicating that 5 !M 1-deoxysphinganine is cytotoxic for both dividing and quiescent 
cells, while lower lipid concentrations are cytostatic. In addition, treatment for only one hour, 
followed by washout and subsequent 23 h incubation was sufficient to reduce the metabolic 
activity of the cells comparably to a continuous 24 h incubation with 1-deoxysphinganine (Fig. 
1F), suggesting a rapid effect of the lipid.  
1-deoxysphinganine triggers p21-mediated senescence and multiple cell death pathways in 
Ins-1 cells 
We then investigated whether the reduction of replication following low 1-deoxysphinganine 
concentration is mediated by induction of senescence. 1 !M 1-deoxysphinganine increased "-
galactosidase activity (Fig. 2A) and nuclear p21WAF1/Cip1 expression (Fig. 2B, C), a hallmark (16) 
and inducer of senescence (17), respectively. To investigate if increased p21 expression was 
sufficient to trigger the senescence pathway in Ins-1 cells, we used adenovirus infection 
overexpressed p21 (Adp21) or GFP (AdGFP) as a control (Fig 2D). Adp21 infection decreased 
Ins-1 cell replication and increased "-galactosidase activity, while both parameters were 
unchanged following AdGFP incubation (Fig 2E, F). In addition, the increased "-galactosidase 
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activity following 1 !M 1-deoxysphinganine treatment or Adp21 infection was accompanied by 
increased MTT reduction/cell (Fig. S2), suggesting increased mitochondrial dehydrogenase 
activity, a parameter associated with cellular senescence (18). These data suggest that up-
regulation of p21 induced by 1 !M 1-deoxysphinganine treatment contributes to the decreased 
Ins-1 replication by activating a senescence program. 
Next, we further explored the cytotoxic effect of high 1-deoxysphinganine concentrations. Five 
!M 1-deoxysphinganine abrogated the expression of p21 and induced cells with condensed 
pyknotic nuclei and high levels of activated caspase-3, hallmarks for the execution phase of 
apoptosis (Fig. 3A, S3A). In addition, FACS analyses of cells co-stained with annexin V and 
propidium iodide  (PI) revealed that 5 !M 1-deoxysphinganine treatment increased the amount of 
both apoptotic and necrotic cells (Fig. 3B, C, S3B),  and induced the cells to arrest in the G0/G1 
phase of the cell cycle (Fig. S4), suggesting that the lipid triggers multiple cell death pathways in 
Ins-1 cells. 
1-deoxysphinganine intracellular metabolites contribute to cytotoxicity in Ins-1 cells  
As treatment with exogenous 1-deoxy-dihydroceramides (m18:0,24:1 and m18:0,16:0) and 1-
deoxy-methylsphinganine, where alanine is replaced by glycine, reduced the cell replication 
similarly to 1-deoxysphinganine treatment (Fig. 4A), we then tested whether exogenous 1-
deoxysphinganine was also metabolized by the cells to the deoxy forms of ceramide. Incubation 
with 1-deoxysphinganine significantly increased the cellular levels of deoxy-dihydroceramide 
with different acyl chain length (Fig. 4B) without altering normal ceramide levels (Fig. S5A), and 
selectively up-regulated the expression of ceramide synthase 5 (Fig. 4C), suggesting that 1-
deoxysphinganine is readily metabolized in Ins-1 cells and accumulates in the acylated form. In 
addition, pre-treatment of Ins-1 cells with the class 2 amphiphile U-18666A, a well-established 
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inhibitor of NPC1 (Niemann–Pick C) protein that prevents intracellular trafficking of 
sphingolipids and cholesterol (19; 20), partially rescued 1-deoxysphinganine-mediated 
cytotoxicity (Fig. 4D, S5B). Moreover, pharmacological inhibition of ceramide synthesis with 
fumonisin B1 was unique in reducing the toxicity of 5 !M 1-deoxysphinganine (Fig.4D, S5C), 
while inhibition of either the first step of sphingolipid synthesis with myriocin or 
glucosylceramide synthesis with 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol  (PPMP) 
had no effect on cell viability (not shown). Collectively, these data indicate that intracellular 
uptake followed by metabolic conversion to 1-deoxy-dihydroceramides is responsible, at least in 
part, for 1-deoxysphinganine toxicity. 
1-deoxysphinganine increases the phosphorylation of selected kinases in Ins-1 cells 
To further characterize the biochemical components of 1-deoxysphinganine-induced cytotoxicity, 
we analyzed the phosphorylated status of key proteins involved in major signaling pathways. 
Western blot quantification revealed increased phosphorylation of JNK and p38 MAPK in 1-
deoxysphinganine treated Ins-1 cells. In addition, the ratio of AKT phosphorylation was 
unchanged upon lipid treatment but the total protein amount increased in presence of 1-
deoxysphinganine (Fig. 5A-C). As kinase activation by phosphorylation suggests a possible role 
of these proteins in 1-deoxysphinganine-mediated phenotype, we tested this hypothesis by 
treating the cells with specific kinase inhibitors. Pre-treatment with the p38 MAPK inhibitor 
Birb796 partially rescued cell replication (Fig. 5D) and reduced 1-deoxysphinganine-induced 
senescence (Fig. 5E). Conversely, the JNK inhibitor SP600125 potentiated cytotoxicity and 
senescence (Fig. 5D, E), and the combined treatment partially rescued the JNK inhibitor effect at 
1 !M 1-deoxysphinganine incubation. These data suggest that p38 MAPK activation is an 
effector of 1-deoxysphinganine cytotoxicity and senescence, while JNK activation plays a 
protective role in Ins-1 cells.  
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1-deoxysphinganine treatment promotes re-organization of the actin cytoskeleton in Ins-1 
cells 
The observed changes in cell morphology observed following 1-deoxysphinganine treatment 
(Fig. 1C) prompted us to further analyze whether the lipid induced cytoskeletal alterations. To 
detect early cytoskeletal re-arrangements, cells were imaged after 5 h of treatment. Phalloidin-
stained actin filaments were mainly concentrated in the cortical area and in filopodia following 
control BSA or sphinganine treatment. However, upon 1-deoxysphinganine incubation, actin 
staining accumulated in punctated structures mainly located in the peri-nuclear area of the cells. 
Different from the actin phenotype, tubulin staining showed a similar microtubule pattern in all 
treatments, suggesting that 1-deoxysphinganine preferentially interferes with the organization of 
actin cytoskeleton in Ins-1 cells (Fig. 6A). Quantitative analysis of members of the Rho family of 
GTPases that regulate intracellular actin dynamics (reviewed in (21)), showed increased levels of 
Rac1 activity (Fig. 6B) and expression of Rac1 and Rho, albeit the latter did not reach 
significance, upon 1-deoxysphinganine treatment (Fig. 6C), suggesting that Rho family GTPases 
may be involved in 1-deoxysphinganine-mediated changes in actin cytoskeleton re-organization. 
Of note, actin alterations were not accompanied by apoptosis at this time point (data not shown). 
In addition, pre-treatment with JNK, p38 MAPK and ceramide synthase inhibitors did not prevent 
actin remodeling (Fig. S6A), suggesting that cytoskeletal and cell cycle effects are modulated by 
different signaling pathways. 
To further characterize whether aberrantly localized actin may intersect with the secretory 
apparatus of the cells, we performed co-staining for actin and insulin. FACS-based single cell 
quantification revealed that the lipid treatment did not alter the cellular content of actin and 
insulin (Fig. S6B). However, confocal analyses showed that filamentous actin accumulated 
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intracellularly in close proximity to and partially co-localized with insulin-containing vesicles 
(Fig. 6D). 
1-deoxysphinganine reduces metabolic activity, insulin secretion and modulates actin 
cytoskeleton in primary islets 
To confirm the relevance of our results in primary cells, we tested whether 1-deoxysphinganine 
affects the functionality of isolated islets. Lipid delivery to the cells was improved by dissociation 
of 1400 islets from 6 Wistar rats into single cells, these were seeded in ECM-coated plates and 
treated for 24 h with 5 !M sphinganine, 1-deoxysphinganine, or BSA as control. Of note, 
dissociated islets plated on ECM are virtually quiescent (R. Zuellig, personal communication).  
Under these experimental conditions, 1-deoxysphinganine treatment induced cellular 
vacuolization (Fig. 7A), and reduced the metabolic activity (Fig. 7B) and, to a lesser extent, the 
number of live cells (Fig. 7C). However, senescence was not observed, as indicated by 
comparable "gal activities (Fig. S7A) and absence of p21 staining (not shown). Similarly to the 
effect in Ins-1 cells, 1-deoxysphinganine treatment induced re-arrangement of actin cytoskeleton 
with the resulting accumulation of actin in intracellular punctated structures (Fig. 7D). 1-
deoxysphinganine did not alter the cellular content of insulin (Fig. S7B) or selectively reduce the 
number of insulin-producing cells (Fig. S7C). However, following incubation with the lipid, 
isolated " cells were unable to regulate insulin secretion in response to glucose stimulation (Fig. 
7E, S7D). Collectively, these data indicate that 1-deoxysphinganine is cytotoxic to isolated 
primary islets# and compromises both functionality and cyto-architecture of " cells.  
Increased glucose levels potentiate 1-deoxysphinganine toxicity  
Our in vitro results showed 1-deoxySL-mediated cytotoxicity in insulin-producing cells, 
suggesting that raised levels of these lipids may contribute to the failure of "-cells during the 
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development of diabetes. However, elevated 1-deoxySLs levels were also found in the plasma of 
patients with metabolic syndrome that did not present hyperglycemia and overt diabetes (5), 
raising the question that increased amount of 1-deoxySLs are not the sole cause of !-cell toxicity 
and that additional factors contribute to the diabetic phenotype. To further investigate the causal 
network of atypical sphingolipids and !-cell toxicity, we analyzed pancreatic islets in leptin 
deficient ob/ob mice. Kept on a normal chow diet, these mice develop obesity and a mild 
hyperglycemia that reverts with aging, as pancreatic !-cell compensation occurs and increased 
insulin levels improve glucose homeostasis (22; 23). 60 week old ob/ob mice had only slightly 
higher plasma glucose levels compared with age matched WT animals, but a robust increase in 
plasma HDL, cholesterol and ALT levels (Fig. S8A), the latter reflecting steatotic liver damage 
(Fig. S8B). As previously shown (23), ob/ob pancreata were characterized by pronounced islet 
hyperplasia, vascularization and robust insulin production (Fig. S8B), suggesting that !-cells 
could compensate for the increased insulin demand without reaching exhaustion. Despite the 
evident hyperplasia, islets did not show active replication at the analyzed age (Fig. S8B). 
Interestingly, quantification of the plasma lipid profiles in ob/ob mice revealed a moderate but 
significant increase of 1-deoxysphinganine levels (Fig. 8A), which was not associated with 
increased senescence or apoptosis (Fig. S8B). In addition, like in human samples (5), sphingosine 
was the most abundant species in the mouse plasma and significantly increased in ob/ob mice 
(Fig. S8C). While it is likely that plasma 1-deoxySLs did not reach a critical concentration 
threshold to induce !-cell failure, absence of other pathological parameters, including 
hyperglycemia, may account for the normal viability of !-cells. To test this hypothesis, we 
incubated Ins-1 cells with 1-deoxysphinganine in presence or absence of glucose. Treatment with 
30mM glucose for 24 h potentiated 1-deoxysphinganine-induced toxicity (Fig. 8B, S8D), 
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suggesting that hyperglycemia and 1-deoxySLs synergize to induce glucolipotoxicity in insulin-
producing cells.  
Discussion 
Elevated levels of 1-deoxySLs have been found in the blood of patients suffering from metabolic 
syndrome and diabetes mellitus (5; 6), raising the question of the role of atypical lipids in the 
development of these pathologies. Our results showed that exposure to 1-deoxySLs in the low 
!M range compromised insulin secretion and triggered senescence and cell death in insulin-
producing cells, indicating that 1-deoxySLs are indeed toxic for these cells. In our experimental 
approach we elucidated 1-deoxysphinganine toxicity at three distinct levels, namely i) changes in 
cellular structure, ii) engagement of signaling molecules and iii) activation of effector proteins. A 
major finding of our study is that 1-deoxysphinganine-mediated toxicity is a complex 
phenomenon and triggers multiple pathways, including cytoskeletal remodeling, senescence, 
necrosis and apoptosis. 
1-deoxysphinganine triggers the re-organization of actin cytoskeleton in insulin-producing cells 
1-deoxysphinganine treatment selectively altered cytoskeleton organization both in Ins-1 cells 
and primary islets, inducing accumulation of filamentous actin in intracellular punctated 
structures juxtaposed to insulin-containing vesicles. Similar but transient actin fiber alterations 
have been observed previously in 1-deoxysphinganine-treated Vero cells (7). In addition, 1-
deoxysphinganine impaired cytoskeleton dynamics in sensory and motoneurons without inducing 
cell death (10). Our study showed not only that the lipid induced actin rearrangements before the 
appearance of apoptotic markers, but also that inhibitors shown to mitigate cytotoxicity did not 
prevent cytoskeletal remodeling. These data suggest that cytoskeleton rearrangements are a direct 
effect of 1-deoxysphinganine incubation rather than a consequence of cell lethality and that 
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cytoskeleton and cell cycle effects are regulated by distinct signaling pathways. In this context, it 
is currently under investigation whether alterations in Rho GTPase activation, reported by (7) and 
our study, are the key conserved molecular mechanism also behind cytoskeletal alteration in 
neurons.  
In the case of !-cells, the early cellular morphological alterations may impair cellular 
functionality, including insulin secretion. Indeed, earlier studies demonstrated that insulin 
secretion in pancreatic !-cells is coupled with re-organization of the filamentous actin web 
located beneath the plasma membrane, thus allowing docking of insulin-containing granules to 
the cell membrane and consequent secretion. Importantly, glucose stimulation directly induces re-
arrangement of the actin web (24; 25), to which insulin-containing granules are in tight contact 
(26). Thus impaired remodeling of actin cytoskeleton resulting from 1-deoxysphinganine 
treatment may contribute to the defective insulin secretion observed in our primary !-cells 
cultures. However, we cannot exclude that additional lipid-induced changes, including altered 
gene transcription, may contribute to the phenotype.  
1-deoxy-dihydroceramide contributes to 1-deoxysphinganine-induced cytotoxicity  
Ceramide is a key intracellular signaling molecule involved in several cellular functions, 
including cell death (reviewed in (27)). Importantly, both cell-permeant analogues of ceramide 
(28) and de novo ceramide synthesis (29) impair insulin secretion and mitogenesis in pancreatic 
!-cells and induce apoptosis (reviewed in (30)), supporting a critical regulatory role for ceramide 
in the metabolic dysfunction of these cells. In the search for the molecular signaling generated by 
1-deoxysphinganine treatment, we explored the hypothesis that 1-deoxysphinganine uptake and 
conversion to 1-deoxy-dihydroceramide is necessary to exert its toxicity. Our mass spectrometry 
and inhibitor analyses supported this hypothesis. In addition, 1-deoxysphinganine increased the 
expression of ceramide synthase 5 (CerS5),   while !-cell lipotoxicity resulting from palmitate 
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treatment stimulated the synthesis of CerS4 (31), suggesting that different lipids stimulate 
specific CerS isoforms. Collectively, our results suggest that some of the cytotoxic effects of 1-
deoxysphinganine occur after its intracellular uptake and metabolism to 1-deoxy-
dihydroceramide. However, we cannot exclude that 1-deoxysphinganine triggers death receptors 
on the cell surface. Given the similarity of the molecular structure of 1-deoxysphinganine and 
sphingosine, it is worthy of further investigation to determine if 1-deoxysphinganine can engage 
or antagonize the same membrane receptors, as previously suggested (8). 
 
1-deoxysphinganine activates multiple intracellular pathways  
In addition to cytoskeletal remodeling, 1-deoxysphinganine treatment induced a complex dose-
dependent pattern of toxicity in Ins-1 cells, characterized by the appearance of p21-induced 
senescence at low doses and apoptosis and necrosis at high doses. Of note, the senescence growth 
arrest was limited to replicating cells, as demonstrated previously (32-34), and quiescent primary 
islets were devoid of senescence markers upon lipid treatment. These data imply that 1-
deoxysphinganine triggers multiple signaling pathways. Indeed, the lipid was shown to 
selectively activate JNK, MAPK, Erk1/2, PKC but not AKT in NIH-3T3, RH-7777, PC-3 and 
LNCaP cell lines (8; 9), while we showed that JNK, p38 MAPK phosphorylation and AKT levels 
increased in Ins-1 cells, indicating that the intracellular signaling effectors stimulated by 1-
deoxysphinganine depend on the cellular context.  As JNK and MAPK are known to be activated 
by intracellular ceramide (35), it is possible that the increased 1-deoxy-dihydroceramide 
synthesis observed in Ins-1 cells activates these kinases. In addition, the fact that the CerS 
inhibitor FB1 was the only compound able to rescue the toxicity of high 1-deoxysphinganine 
doses, suggests that increased ceramide (or its deoxy form) synthesis is upstream of or a 
prerequisite for the activation of different signaling effectors. 
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While a more in depth analysis of the set of kinases activated by 1-deoxysphinganine is needed to 
elucidate the precise downstream signaling cascade, our inhibitor studies revealed an intriguing 
antagonistic role of JNK and p38 MAPK in the context of 1-deoxysphinganine-induced 
senescence. Interestingly, a similar dose-dependent senescence-apoptosis transition and opposite 
effect of p38 MAPK and JNK on senescence has been reported in endothelial progenitor cells 
upon doxorubicin treatment (36), further confirming that different kinases activated by the same 
stimulus may exert opposite cellular effects.  
In conclusion, our work shows that 1-deoxysphinganine treatment and its conversion to 1-deoxy-
dihydroceramide compromises the viability of insulin-producing cells via multiple pathways. 
This indicates that, similar to free fatty acids (reviewed in (30)), 1-deoxySLs induce lipotoxicity 
but with higher efficiency (low !M for 1-deoxySLs versus low mM for free fatty acids (31; 37; 
38)). However, our in vivo study, together with the fact that HSAN1 and metabolic syndrome 
patients have elevated 1-deoxysphinganine levels without overt diabetes, suggests that the raised 
amount of 1-deoxysphinganine observed in vivo is not sufficient to directly induce !-cell failure 
but would require  additional pathological parameters, for instance an established chronic 
hyperglycemic state, to promote !-cell toxicity (39). In this context, targeting 1-deoxySL 
synthesis as a combination therapeutic strategy for diabetes mellitus warrants further 
investigations. 
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Figure legends 
Figure 1. Deoxysphingolipids decrease the replication of Ins-1 cells. A. Metabolic activity tested 
by MTT assay of Ins-1 cells treated at 50% (low density, L) and 90% (high density, H) 
confluence with sphinganine (SA) and 1-deoxysphinganine (dSA) at the indicated concentrations 
and incubated for 24 h. B. Enumeration of live cells treated with the indicated dSA 
concentrations for 24 h. Note that the number of cells treated with 1 !M dSA is comparable to 
the initial seeding density. C. Bright field images showing cell rounding up upon 24 h dSA 
treatment. D. Quantification of trypan blue positive cells after treatment with the indicated 
concentrations of dSA for 24 h. Data are expressed as percentage of total cell number. E. 
Quantification of LDH released in the medium after 24 h dSA treatment. Data are normalized to 
the number of cells. F. MTT assay of Ins-1cells treated with dSA for the indicated time and 
assessed 24 h after adding the lipid. Results are average ± SEM (n=3), *p<0.05. Scale bars: 50 
!m. 
Figure 2. 1-deoxysphinganine triggers senescence in Ins-1 cells. A. Quantification of "-
galactosidase activity following incubation for 24 h with 1 !M  sphinganine (SA), 0.5 and 1 !M  
1-deoxysphinganine (dSA), or BSA as control (cntl). Values are normalized to the number of live 
cells. B. Immunofluorescence imaging showing nuclear expression of p21 following incubation 
for 24 h with 1 !M SA, 1 !M dSA, or BSA as control (cntl). Nuclei are stained with DAPI 
(blue). Lower panels show nuclear localization of p21. C. Western blot and densitometric 
quantification of p21/GAPDH levels following incubation for 24 h with 1 !M SA, 1 !M dSA or 
BSA as control. D. Immunostaining of p21 (upper panels) or live imaging (lower panel) of Ins-1 
cells infected with p21 (Adp21) and GFP (AdGFP) adenoviruses at multiplicity of infection 
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(MOI) of 50. E. Enumeration of live Ins-1 cells 24 h after Adp21 or AdGFP infection. Note how 
Adp21 decreased the replication of Ins-1 cells in a dose response manner without inducing cell 
death. F. Quantification of !-galactosidase activity 24 h after Adp21 or AdGFP infection. Note 
how senescence is induced only in presence of Adp21. Results are average ± SEM (n=3), 
*p<0.05. Scale bars: 50 "m. 
Figure 3. 1-deoxysphinganine triggers apoptosis and necrosis in Ins-1 cells. A. Left panel. 
Quantification of cleaved caspase 3 (CC-3) and p21 positive cells after 24 h incubation with 5 
"M sphinganine, 1 and 5 "M 1-deoxysphinganine (dSA) or BSA as control. Right panel. 
Immunofluorescence imaging showing cytosolic expression of cleaved caspase 3 (CC-3). Note 
the pyknotic nuclei in CC-3 positive cells (arrows). Nuclei are stained with DAPI (blue). Results 
are average ± SEM (n=3), *p<0.05. Scale bars: 50 "m. B. FACS analyses of Ins-1 cells after 24 h 
incubation with 1 and 5 "M dSA or BSA as control and staining with PI and annexin V. C. 
Quantification of cells PI/ annexin V negative (live cells), PI positive (necrotic cells), annexin V 
positive (apoptotic cells) and double positive. Total population consisted of 20’000 cells. Note 
the increased lethality of cells treated with 5 "M 1-dSA. 
Figure 4. 1-deoxy-dihydroceramide contributes to 1-deoxysphinganine-induced cytotoxicity in 
Ins-1 cells. A. MTT assay of Ins-1cells incubated for 72 h with sphinganine (SA), sphingosine 
(SO), 1-deoxysphinganine (dSA), deoxy-methylsphinganine (dmethSA), deoxy-
dihydroceramides (1-deoxy-dh-Cer m18:0,24:1 and m18:0,16:0). B. Mass spectrometry 
quantification shows the increased formation of 1-deoxy-dh-Cer with different acyl chain length 
upon 24 h treatment with 3 "M 1 dSA. SA, SO and BSA incubation were used as control. C. 
RNA expression levels of different ceramide synthase (CerS) isoforms following lipid incubation 
as in B. Transcript levels were normalized using GAPDH RNA as a reference. D.   Enumeration 
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of live cells following incubation for 24 h with dSA in presence or absence of 5 !M U-18666A or 
35 !M fumonisin B1 (FB1). Results are average ± SEM (n=3), *p<0.05.  
Figure 5. 1-deoxysphinganine increases the phosphorylation of selected kinases in Ins-1 cells. A. 
Western blot of phosphorylated and total levels of JNK, p38 and AKT following incubation for 
24 h with 1 !M sphinganine (SA), 1 !M 1-deoxysphinganine (dSA) or BSA as control. B. 
Densitometric quantification of protein phosphorylation/total protein/actin levels. Data are 
expressed as percentage of control (cntl). C. Densitometric quantification of total protein/actin 
levels. Data are expressed as percentage of control (cntl).  D. Enumeration of live cells treated 
with the indicated dSA concentrations for 24 h in presence of 10 !M of inhibitors of p38 MAPK 
(Birb796, Birb), JNK (SP600125, SP) or a combination of Birb796 and SP600125 (B/SP). Cells 
were pre-treated for 1 hour with the indicated inhibitors before addition of 1-deoxySA. E. 
Quantification of "-galactosidase activity following incubation for 24 h with 1 !M  dSA in 
presence of 10 !M of inhibitors of p38 MAPK (Birb796, Birb), JNK (SP600125, SP) or a 
combination of Birb796 and SP600125 (B/SP). Values are normalized to the number of live cells. 
Results are average ± SEM (n=3), *p<0.05.  
Figure 6. 1-deoxysphinganine incubation induced actin cytoskeleton rearrangements. A. Ins-1 
cells treated with 5 !M 1-deoxysphinganine (dSA), sphinganine (SA) or BSA as control for 5 h 
and stained with phalloidin (green, left panels) or anti-tubulin antibody (red, right panels). Nuclei 
are stained with DAPI (blue). Note the actin staining in punctated structures following dSA 
treatment (arrows in left panel). In the right panels, arrows indicate tubulin midbody in recently 
divided cells and arrowhead the mitotic spindle. Scale bars: 50 !m. B. Rac1 activity following 5 
h treatment with 5 !M dSA, 5 !M SA or BSA as control. NC, negative control. Constitutively 
active Rac1 (RCCA) was used as a positive control. C. Western blotting quantification of Rac1 
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and RhoA expression upon 24 h treatment with 1 !M dSA, 1 !M SA or BSA as control. Results 
are average ± SEM (n=3), *p<0.05. D. Confocal images of Ins-1 cells treated with 5 !M dSA or 
BSA as a control for 5 h and stained with phalloidin (green) or anti-insulin antibody (red). Nuclei 
are stained with DAPI (blue). Signal intensities representing the voxel space of the reconstructed 
image stacks are depicted as scatterplots showing partial signal overlap of actin and insulin in cntl 
and dSA-treated samples.  Robust overlap of actin and "-catenin signals (dots accumulated in the 
mid-diagonal of the plot) and limited overlap of actin and DAPI (dots preferentially distributed 
along the axes) were used as a control. Nuclei are stained with DAPI (blue). Scale bars: 10 !m. 
Figure 7. 1-deoxysphinganine treatment is cytotoxic for rat primary islets. Dissociated islets 
were plated on ECM plates and treated for 24 h with 5 !M sphinganine (SA), 5 !M 1-
deoxysphinganine (dSA), and BSA as control. A. Quantification of vacuolized cells following 
lipid treatment. Data are expressed as percentage of total cell number. Right panels: bright field 
images of treated cells showing cell vacuolization (arrows and inset) upon dSA treatment. B. 
Metabolic activity tested by MTT assay. Data are expressed as percentage of BSA-treated control 
cells. C. Enumeration of live cells following lipid treatment. D. Quantification of insulin 
secretion stimulated with 3.3 mM (Low I), 16.7 mM (High) and 3.3 mM (Low II) glucose 
following incubation for 24 h with the lipids. Secreted insulin was normalized to the cell number. 
E. Filamentous actin (phalloidin, green) and insulin (red) co-staining of treated islets. Nuclei are 
stained with DAPI (blue). Results are average ± SEM (n=3), *p<0.05. Scale bars: 50 !m. 
Figure 8. A. Mass spectrometry quantification of 1-deoxysphinganine (dSA) serum levels of 60 
week old wild type (WT) and ob/ob mice. Results are average ± SEM (n=5), *p<0.05. B. 
Enumeration of live Ins-1 cells treated with the indicated dSA concentrations for 24 h in presence 
(Gluc) or absence (Cntl) of 30 mM glucose. Results are average ± SEM (n=3), *p<0.05.  
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Supplementary Online Material  
List of antibodies 
Primary antibodies used for immunostaining were: Alexa Fluor 594 phalloidin (Life 
Technologies), anti-Dtubulin (Cell Signaling), anti-Rac1 (Abcam), anti-cleaved caspase-3 (Cell 
Signaling), anti-p21 (Abcam), anti-insulin (Dako), anti-glucagon (Sigma), fluorescein-conjugated 
Annexin V (BD Pharmingen). Fluorophore-conjugated secondary antibodies were from 
$OH[DIOXRU1XFOHLZHUHYLVXDOL]HGZLWKƍ-diamidino-2-phenylindole (DAPI). 
Primary antibodies used for western blotting were: anti-p21 (Abcam), anti-GAPDH (Santa Cruz), 
anti-RhoA (Santa Cruz), anti-Rac1 (BD Biosciences), anti-phospho JNK and anti-JNK (R&D 
System), anti-phospho p38MAPK and anti-p38MAPK, anti-phospho AKT and anti-AKT (all 
from Cell Signaling) and anti-ȕ-actin (Sigma). Secondary HRP-conjugated antibodies were from 
Jackson ImmunoResearch. 
Ceramide synthase primers for qPCR  
Rat CerS1: rat CerS1_LC_F:  AGTGCCTGGAAGCTTCTGTT,  
rat CerS1_LC_R:  GACCTCCAGCCGTAGAAGAC 
Rat CerS2: rat CerS2_LC_F:  TTGAGGAAAGTTTGGGAAGG,  
rat CerS2_LC_R:  AAACCAGGAGAAGCAGAGGA 
Rat CerS3: rat CerS3_LC_F:  TGCCACACCTCTAGCCAATG,  
rat CerS3_LC_R:  CCTGGCGCTCTGTCAAGTTA 
Rat CerS4: rat CerS4_LC_F:  TCACTCTGCCCTTTGACATC,  
rat CerS4_LC_R:  TGACGCTGTAGGAGAAGACG 
Rat CerS5: rat CerS5_LC_F:  CACACAGCTGGCCTTCTACT, 
 rat CerS5_LC_R:  ACTCGCACCATGTTGTTGAT 
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Rat CerS6: CerS6_F:  GGGATCTTAGCCTGGTTCTGG,  
CerS6_R:  GCCTCCTCCGTGTTCTTCAG 
Rat(Mouse)GAPDH: rat GAPDH_LC_F:  GGTCGGTGTGAACGGATTTG, 
rat GAPDH_LC_R:  TTGCCGTGGGTAGAGTCATA 
 
Figure legends 
Figure S1. A. Comparison of Ins-1 metabolic activity by MTT and WST-1 reduction following 
24 h incubation with 1-deoxysphinganine (dSA) at the indicated concentrations. BSA incubation 
was used as a control. Results are average ± SEM (n=3). B. Expression profile of genes involved 
in different cell death pathways following 1 PM dSA compared to 1 PM sphinganine incubation 
by Rat Cell Death Pathway Finder PCR Array (SABiosciences). 1 PM 1-deoxysphinganine 
treatment moderately up-regulated genes involved in necrosis, autophagy and apoptosis 
(Olr1583, Ctss, Esr1, Casp1, Fas), while anti-apoptotic genes (Bcl2a1d, Tnfrsf11b) were down-
regulated. C. Analysis of extracted RNA integrity by Agilent 2100 Bioanalyzer. Examples of 
electrophoresis runs and assigned RNA integrity number (RIN) are shown.  D. List of genes 
present in the array. 
Figure S2. Analysis of MTT reduction /cell number following 24 h of 1-deoxysphinganine (dSA) 
treatment (A) or Adp21 and AdGFP infection (B). Data are expressed as percentage of control. 
Results are average ± SEM (n=5), *p<0.05. 
Figure S3. 1-deoxysphinganine triggers apoptosis in Ins-1 cells. A. Co-staining with cleaved 
caspase 3 (CC-3, red) and p21 (green) showing the mutually exclusive expression of the proteins 
upon incubation for 24 h with 5 PM sphinganine, 1 and 5 PM 1-deoxysphinganine or BSA as 
control. Nuclei are stained with DAPI (blue). Scale bars: 50 Pm. B. FACS based quantification of 
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dead cells following 24 h incubation with 1 and 5 PM dSA or BSA as control as determined by 
FSC and SSC parameters shown in Fig. 3. 
Figure S4. Cell cycle analysis by quantification of DNA content in Ins-1 cells after 24 h 
incubation with 1 and 5 PM 1-deoxysphinganine (dSA) or BSA as control. The amount of cells in 
different cell cycle phases is plotted in the lower panel. Total population consisted of 20’000 
cells. Note the decreased amount of cells in G2/M phase and accumulation in G0/G1 phase 
following 5 PM 1-deoxysphinganine treatment. 
Figure S5. A. Mass spectrometry quantification of ceramides in Ins-1 cells treated for 24 h with 
3 PM of sphinganine (SA), sphingosine (SO), 1-deoxysphinganine (dSA) and BSA as control. B. 
MTT assay following incubation for 24 h with SA or dSA in presence or absence of 5 PM U-
18666A (U). C. Bright field images of Ins-1 cells showing reduced toxicity following 5 PM dSA 
treatment in presence of FB1. Results are average ± SEM (n=3), *p<0.05. Scale bars: 50 Pm. 
Figure S6.  A. Ins-1 cells were treated with 10 PM of inhibitors of JNK (SP600125, SP), p38 
MAPK (Birb796, Birb) or 35PM ceramide synthase inhibitor FB1 for 1 h, followed by 5 h 
treatment with 5 PM 1-deoxysphinganine (dSA), sphinganine (SA) or BSA and phalloidin 
staining. Nuclei are stained with DAPI (blue). Scale bars: 50 Pm. B. FACS-based quantification 
of actin and insulin cellular content following 5 h treatment with 5 PM dSA, SA or BSA. 
Figure S7. Dissociated islets were plated on ECM plates and treated for 24 h with 5 PM 
sphinganine (C18SA), 1-deoxysphinganine (dSA), and BSA as control. A. Quantification of E-
galactosidase activity normalized by the cell number. B. Quantification of cellular insulin 
content. Cells were lysed and total insulin level was normalized by the cell number. C. 
Enumeration of insulin-expressing cells. Data are expressed as percentage of total cell number. 
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D. Quantification of insulin secretion stimulated with 3.3 mM (Low I), 16.7 mM (High) and 3.3 
mM (Low II) glucose following incubation for 24 h with the lipids. Secreted insulin was 
normalized by the total insulin content. Results are average ± SEM (n=3), *p<0.05.  
Figure S8. A. Weight and blood parameters of WT and ob/ob mice. B. Histological morphology 
(HE staining) of paraffin embedded liver and pancreas sections from WT and ob/ob mice. Note 
the accumulation of lipid deposit and steatotic phenotype in the latter. Staining of 
insulin/glucagon, replicating (Ki67), senescent (p21) and apoptotic cells (TUNEL) in islets of 60 
week old wild type (WT) and ob/ob mice. Nuclei are stained with DAPI (blue). Scale bars: 50 
PM. D. Mass spectrometry quantification of serum levels of total sphingoid bases after 
hydrolyzing the head group and N-linked fatty acid. Results are average ± SEM (n=5), *p<0.05. 
E. MTT assay of Ins-1 cells incubated for 24 h with 1-deoxysphinganine in presence (Gluc) or 
absence (Cntl) of 30 mM glucose. Results are average ± SEM (n=3), *p<0.05.  
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